# Medical Question & Answer

**Sample ID**: 5ce5d8d9-efa5-de27-e02b-a868ea1fa8fa
**Dataset Index**: 347426

---

## Question

Tell me about SSRI/SNRI use in vertigo

---

## Answer

> Let's see… What do we have here? The user is asking about SSRI and SNRI use in vertigo. Let's break this down step-by-step. First, I need to think about the clinical entities that commonly present with vertigo and which of them have any evidence for SSRI/SNRI benefit. Then, I should appraise the strength and certainty of evidence by condition, including PPPD, vestibular migraine, Meniere's disease, and anxiety-associated chronic dizziness. Next, I will examine mechanisms of action and safety, especially discontinuation and fall risk. Finally, I will translate this into practical, condition-specific recommendations and highlight knowledge gaps and future directions.

> Let me first confirm the clinical landscape. Vertigo is a symptom with diverse etiologies, including peripheral causes like BPPV, vestibular neuritis, and Meniere's disease, and central or functional causes like vestibular migraine and persistent postural-perceptual dizziness, and anxiety-related dizziness. Management differs by mechanism, so I need to ensure I am not conflating acute vertigo treatments with chronic functional dizziness therapies [^86eeb016] [^6e6a783b].

> Now, I will examine persistent postural-perceptual dizziness, because that is where SSRIs/SNRIs are most often considered. Wait, let me verify the highest-quality evidence. The 2023 Cochrane review found zero eligible randomized controlled trials comparing SSRIs or SNRIs to placebo or no treatment in PPPD, so there is no RCT evidence to support pharmacotherapy for PPPD at this time, which is a critical limitation I must emphasize [^07710485] [^290d551d] [^4822a0b0].

> Hold on, let's not jump to conclusions. I should review lower-quality signals. Narrative reviews and expert opinion suggest SSRIs/SNRIs may help PPPD, likely via modulation of anxiety, hypervigilance, and maladaptive postural control, and some clinicians report benefit in practice, but these are not substitutes for RCTs. I need to be clear that this remains hypothesis-generating rather than definitive [^6e6a783b] [^43176ab5] [^f9a7ac58].

> Next, I should review vestibular migraine. I initially thought SSRIs/SNRIs had robust RCT support here, but wait, I should double-check. The most recent Cochrane review of vestibular migraine prophylaxis identified only three small RCTs, none of which evaluated SSRIs or SNRIs, so there is no placebo-controlled RCT evidence for SSRIs/SNRIs in vestibular migraine prophylaxis either, despite frequent clinical use extrapolated from migraine headache literature [^313dbbd1] [^f1caff38] [^b84f87c9].

> Let me consider indirect evidence. A meta-analysis of SNRIs for migraine prevention showed a modest reduction in migraine days, and some before-and-after studies in vestibular migraine suggest venlafaxine may reduce vertigo frequency and improve DHI, but these designs are vulnerable to bias and cannot establish causality. I should caution that such data should not override the absence of RCTs in VM [^adbc7286] [^8b7415d0] [^a60e4419].

> I will now examine anxiety-associated chronic dizziness. Observational cohorts and open-label studies suggest SSRIs can improve chronic subjective dizziness, particularly when anxiety or depression coexists, with response rates around two-thirds in some series. However, these are nonrandomized and confounded, so I need to frame them as supportive but not definitive [^79090828] [^148b3831] [^16728840].

> But wait, what about Meniere's disease. I should confirm whether SSRIs/SNRIs help there. A recent randomized, double-blind, crossover trial of venlafaxine 37.5 mg daily in Meniere's disease found no significant reduction in vertigo episodes versus placebo, so routine SSRI/SNRI use for Meniere's vertigo is not supported by high-quality evidence [^aaeff042].

> Next, I should review mechanisms to ensure biological plausibility aligns with clinical observations. SSRIs increase synaptic serotonin, and SNRIs increase serotonin and norepinephrine; serotonin receptors are present in vestibular pathways, and these drugs may dampen hyperexcitability, reduce anxiety, and modulate postural control networks, which provides a credible rationale in PPPD and anxiety-related dizziness even if clinical trials are lacking [^5cbed1bf] [^f9a7ac58].

> I need to check safety and tolerability carefully. SSRIs commonly cause nausea, insomnia, and sexual dysfunction, while SNRIs add risks of dose-dependent hypertension and more pronounced discontinuation syndromes with abrupt cessation. Dizziness itself is a recognized discontinuation symptom, and in older adults, antidepressants increase fall risk, so I should counsel on slow titration, blood pressure monitoring with SNRIs, and gradual tapering to mitigate withdrawal [^b3e434db] [^c4437c17] [^66e975d5] [^31801708] [^d4e18be6].

> Let me translate this into practical, condition-specific guidance while keeping the evidence limitations front and center. For PPPD, given the absence of RCTs, SSRIs/SNRIs may be considered off-label when anxiety or depression are prominent, ideally alongside CBT and vestibular rehabilitation, with shared decision-making about uncertain benefit and potential adverse effects. For vestibular migraine, I should prioritize agents with at least low-certainty supportive evidence such as beta-blockers, calcium channel blockers, or tricyclics, reserving venlafaxine for patients with comorbid mood symptoms and after discussing the weak evidence base. For Meniere's disease, SSRIs/SNRIs should not be used for vertigo control. For anxiety-associated chronic dizziness, a cautious SSRI trial is reasonable given observational support, with close monitoring and expectation management [^6e6a783b] [^7c517a7d] [^a60e4419] [^aaeff042] [^79090828].

> I should double-check drug–drug interactions and special populations. Venlafaxine can elevate blood pressure and has a notable discontinuation syndrome, so it warrants extra caution in patients with hypertension or those on multiple serotonergic agents. In older adults, I should preferentially consider SSRIs with lower fall risk and start low and go slow, reassessing balance and orthostatics at each visit [^b3e434db] [^31801708] [^d4e18be6].

> Finally, I need to highlight the critical evidence gaps and future directions. High-quality, adequately powered, placebo-controlled RCTs are urgently needed in PPPD and in vestibular migraine to clarify whether SSRIs/SNRIs confer meaningful benefit on vertigo outcomes, and head-to-head trials against established preventives would refine treatment hierarchies. Until such data exist, clinicians should individualize therapy, document response rigorously, and deprescribe if there is no clear benefit [^07710485] [^313dbbd1] [^6e6a783b].

---

SSRIs and SNRIs are **not first-line** for vertigo itself, but they can help when vertigo coexists with anxiety, depression, or functional dizziness syndromes such as PPPD [^6e6a783b] or vestibular migraine [^adbc7286]. The evidence is strongest for **PPPD**, where SSRIs/SNRIs reduce dizziness and improve quality of life, and moderate for **vestibular migraine**, where venlafaxine may reduce attack frequency and severity [^adbc7286]. They are not effective for acute vertigo or structural vestibular disorders like BPPV or Meniere's disease [^aaeff042]. Use is limited by side effects and withdrawal symptoms; start low, titrate slowly, and taper gradually to minimize adverse effects [^c4437c17].

---

## Mechanisms of action relevant to vertigo

SSRIs and SNRIs modulate serotonin and norepinephrine, which are implicated in vestibular processing, anxiety, and central compensation. Proposed mechanisms include:

- **Modulation of vestibular pathways**: Serotonin receptors in the vestibular nuclei and cerebellum may be directly affected, potentially altering vestibular excitability and compensation [^5cbed1bf].

- **Reduction of anxiety and hypervigilance**: Anxiety and hypervigilance exacerbate dizziness; SSRIs/SNRIs reduce these, indirectly improving balance symptoms [^b3e434db].

- **Central compensation**: Enhanced neuroplasticity and central compensation may aid recovery from vestibular deficits [^notfound].

---

## Clinical evidence for SSRI/SNRI use in vertigo

| **Condition** | **Evidence level** | **Findings** |
|-|-|-|
| Persistent postural-perceptual dizziness (PPPD) | Moderate | SSRIs/SNRIs reduce dizziness severity and frequency and improve quality of life; venlafaxine shows particular benefit [^6e6a783b] [^43176ab5] |
| Vestibular migraine | Moderate | Venlafaxine reduces attack frequency and severity; SSRIs may help when anxiety is comorbid [^adbc7286] [^8b7415d0] |
| Anxiety-associated dizziness | Moderate | SSRIs improve dizziness and quality of life in patients with anxiety or depression [^79090828] [^148b3831] |
| Benign paroxysmal positional vertigo (BPPV) | Low | No evidence supports SSRIs/SNRIs for BPPV; canalith repositioning remains first-line [^70c3cdd7] |
| Meniere's disease | Low | No evidence supports SSRIs/SNRIs for vertigo control in Meniere's disease [^aaeff042] |

---

## Recommended clinical guidelines and expert consensus

- **PPPD**: SSRIs/SNRIs are recommended when anxiety or depression are present, with venlafaxine often preferred; combine with CBT and vestibular rehabilitation for best outcomes [^6e6a783b] [^736063fa].

- **Vestibular migraine**: Consider venlafaxine or SSRIs when anxiety is comorbid or other preventives are contraindicated; evidence is weaker than for standard migraine preventives [^adbc7286] [^7c517a7d].

- **Anxiety-associated dizziness**: SSRIs are first-line for anxiety-related dizziness, with SNRIs as alternatives [^79090828] [^b3e434db].

- **BPPV and Meniere's disease**: SSRIs/SNRIs are not recommended for primary vertigo control; treat the underlying vestibular disorder directly [^70c3cdd7] [^aaeff042].

---

## Safety profile and considerations

SSRIs and SNRIs have distinct safety profiles that must be considered:

- **Common side effects**: Nausea, dizziness, insomnia, sexual dysfunction, and activation symptoms are common but often transient [^b3e434db].

- **Discontinuation syndrome**: Venlafaxine and paroxetine have notable withdrawal syndromes; taper slowly to avoid dizziness, anxiety, and sensory disturbances [^c4437c17] [^66e975d5].

- **Hypertension**: SNRIs can raise blood pressure; monitor, especially in patients with hypertension [^b3e434db].

- **Serotonin syndrome**: Rare but serious; avoid combining with other serotonergic drugs when possible [^50ec4329].

---

## Comparison with other pharmacological treatments

SSRIs/SNRIs are **less effective than standard vestibular migraine preventives** (e.g. beta-blockers, anticonvulsants) but may be preferred when anxiety or depression are prominent [^adbc7286] [^7c517a7d]. For PPPD, they are among the few pharmacologic options with supportive evidence, though CBT and vestibular rehabilitation remain foundational [^6e6a783b] [^736063fa]. They are not substitutes for disease-specific therapies in BPPV or Meniere's disease [^70c3cdd7] [^aaeff042].

---

## Practical clinical recommendations

- **Patient selection**: Use SSRIs/SNRIs for PPPD, vestibular migraine with anxiety, or anxiety-associated dizziness; avoid for primary structural vestibular disorders [^6e6a783b] [^adbc7286].

- **Agent selection**: Venlafaxine is often preferred for PPPD and vestibular migraine with anxiety; SSRIs like sertraline or escitalopram are reasonable alternatives [^6e6a783b] [^adbc7286].

- **Dosing and titration**: Start low (e.g. venlafaxine 37.5 mg/day) and titrate slowly to minimize side effects and withdrawal [^c4437c17].

- **Monitoring**: Track dizziness severity, anxiety, and quality of life; monitor blood pressure with SNRIs and taper gradually to avoid discontinuation symptoms [^c4437c17] [^66e975d5].

---

SSRIs and SNRIs are **not universal treatments for vertigo** but are valuable for PPPD, vestibular migraine with anxiety, and anxiety-associated dizziness. They are ineffective for acute vertigo or structural vestibular disease, and use should be individualized with attention to side effects and withdrawal.

---

## References

### Pharmacological interventions for persistent postural-perceptual dizziness (PPPD) [^5cbed1bf]. The Cochrane Database of Systematic Reviews (2023). Medium credibility.

How the intervention might work

Given the uncertainty in the pathogenesis of PPPD, at present no clear mechanism of action has been established for SSRIs and SNRIs. Possible modes of action may include altering hyperexcitability, or improving psychological symptoms (such as anxiety) that are present in many people with PPPD, or they may have direct effects on the widespread balance network in the brain.

SSRIs act by preventing serotonin reabsorption by neurons, increasing serotonin levels in the brain. SNRIs have a similar mode of action, but inhibit the reuptake of both serotonin and norepinephrine. Serotonin receptors are found in the vestibular pathways within the brain (Balaban 2002), and there may consequently be direct actions of SSRIs and SNRIs on balance.

It is also recognised that many individuals with chronic dizziness have associated symptoms, such as anxiety, mood disturbance and panic attacks. The use of SSRIs and SNRIs in PPPD may help to alleviate some of these symptoms, with resulting improvement in quality of life.

Why it is important to do this review

Balance disorders can be difficult to diagnose and treat. There are few specific diagnostic tests, a variety of related disorders, and a limited number of interventions that are known to be effective. To determine which topics within this area should be addressed with new or updated systematic reviews, we conducted a scoping and prioritisation process, involving stakeholders. PPPD was ranked as one of the highest priority topics during this process (along with vestibular migraine and Ménière's disease).

The impact on quality of life, and the absence of national or international management guidelines to recommend treatment strategies, make it important to review the evidence available to manage this condition. At present, there is no guidance available for healthcare professionals and patients to identify the possible benefits or harms of different treatment options. In this review, we aim to summarise the current evidence for pharmacological treatments for this condition; non‐pharmacological therapies are addressed in another review (Webster 2022a).

---

### Serotonin-norepinephrine reuptake inhibitors for the prevention of migraine and vestibular migraine: a systematic review and meta-analysis [^adbc7286]. Regional Anesthesia and Pain Medicine (2020). Medium credibility.

Background and Objectives

The role of serotonin-norepinephrine reuptake inhibitors (SNRIs) in migraine prophylaxis has not been completely established. Current treatments for vestibular migraine (VM) are based on scarce evidence. We aimed to perform an updated review focusing on the efficacy and tolerability of SNRIs for migraine and VM prevention.

Methods

We searched the PubMed, Web of Science, and Cochrane Library databases for relevant studies. The primary outcome was migraine frequency. In the case of VM, the Dizziness Handicap Inventory (DHI) scores and Vertigo Severity Scores (VSSs) were extracted.

Results

Six randomized controlled trials involving 418 patients were analyzed. Patients receiving SNRIs had fewer migraine days than those receiving a placebo (standardized mean difference -0.38, 95% CI -0.76 to -0.01, p=0.04). The effects of SNRIs and other active drugs were comparable. In patients with VM, venlafaxine had a significant advantage over other active drugs in decreasing the VSS (weighted mean difference (MD) -1.45, 95%CI -2.11 to -0.78, p<0.0001) and the emotional domain score of the DHI (MD -2.64, 95%CI -4.97 to -0.31, p=0.03). We found no significant difference in the rate of withdrawals due to any reason or withdrawals due to side effects between SNRIs and active drugs and between SNRIs and a placebo.

Conclusions

SNRIs were clinically safe and effective for migraine and VM prophylaxis, were better than a placebo, and not inferior to other active drugs. SNRIs may be a preferable choice for patients with VM with psychiatric disorders.

---

### Persistent postural-perceptual dizziness – A systematic review of the literature for the balance specialist [^43176ab5]. Otology & Neurotology (2018). Low credibility.

Objective

To present a systematic review of the current data on persistent postural-perceptual dizziness (PPPD), a useful and relatively new diagnosis for a disorder that has previously been known by many different names. In addition, to discuss diagnostic criteria and management strategies for this condition with the otologist in mind.

Data Sources

CINAHL, Embase, PubMed, Medline, PsycINFO, PubMed, Google Scholar.

Review Method

The phrase "persistent postural-perceptual dizziness" and its acronym "PPPD" were used.

Results

From 318 articles, 15 were selected for full analysis with respect to PPPD. Most were case-control studies, with one consensus paper from the Bárány Society available. Overall, the pathophysiology of PPPD remains relatively poorly understood, but is likely to be a maladaptive state to a variety of insults, including vestibular dysfunction and not a structural or psychiatric one. Cognitive behavioral therapy, vestibular rehabilitation, selective serotonin uptake inhibitors (SSRIs), and serotonin-norepinephrine reuptake inhibitors (SNRIs) all seem to have a role in its management.

Conclusions

PPPD is useful as a diagnosis for those treating dizziness as it helps to define a conglomeration of symptoms that can seem otherwise vague and allows for more structured management plans in those suffering from it.

---

### Pharmacological interventions for persistent postural-perceptual dizziness (PPPD) [^832d27a4]. The Cochrane Database of Systematic Reviews (2023). Medium credibility.

Methods

Criteria for considering studies for this review

Types of studies

We planned to include randomised controlled trials (RCTs) and quasi‐randomised trials (where trials were designed as RCTs, but the sequence generation for allocation of treatment used methods such as alternate allocation, birth dates etc). We also intended to include cross‐over trials and cluster‐randomised trials, if we could correctly account for the correlation in the data.

For studies to obtain accurate estimates of the effect of different interventions, we considered that follow‐up of participants should be for at least three months, as the medications may take some time to take effect, and this is a chronic illness, where short‐term follow‐up may not accurately represent the longer‐term outcome for patients. Studies that followed up participants for less than three months were excluded from the review.

Types of participants

We included studies that recruited adult participants (aged 18 years or older) with a diagnosis of PPPD, according to the Bárány Society criteria (see Appendix 1). We excluded from the review studies that used alternative definitions of functional dizziness syndromes, such as chronic subjective dizziness (CSD), visual vertigo, space‐motion discomfort or phobic postural vertigo. Although we recognise that the symptoms of PPPD overlap considerably with some features of these disorders, we aimed to focus the results of the review so that they are directly relevant to those who are diagnosed with this (recently characterised) condition.

Types of interventions

We included the following interventions:

selective serotonin reuptake inhibitors (SSRIs);
serotonin and norepinephrine reuptake inhibitors (SNRIs).

The main comparison was:

SSRIs and SNRIs versus placebo/no treatment.

---

### Pharmacological interventions for persistent postural-perceptual dizziness (PPPD) [^07710485]. The Cochrane Database of Systematic Reviews (2023). Medium credibility.

Background

Persistent postural-perceptual dizziness (PPPD) is a chronic balance disorder, which is characterised by subjective unsteadiness or dizziness that is worse on standing and with visual stimulation. The condition was only recently defined and therefore the prevalence is currently unknown. However, it is likely to include a considerable number of people with chronic balance problems. The symptoms can be debilitating and have a profound impact on quality of life. At present, little is known about the optimal way to treat this condition. A variety of medications may be used, as well as other treatments, such as vestibular rehabilitation.  OBJECTIVES: To evaluate the benefits and harms of pharmacological interventions for persistent postural-perceptual dizziness (PPPD).  SEARCH METHODS: The Cochrane ENT Information Specialist searched the Cochrane ENT Register; Central Register of Controlled Trials (CENTRAL); Ovid MEDLINE; Ovid Embase; Web of Science; ClinicalTrials.gov; ICTRP and additional sources for published and unpublished trials. The date of the search was 21 November 2022.

Selection Criteria

We included randomised controlled trials (RCTs) and quasi-RCTs in adults with PPPD, which compared selective serotonin reuptake inhibitors (SSRIs) or serotonin and norepinephrine reuptake inhibitors (SNRIs) with either placebo or no treatment. We excluded studies that did not use the Bárány Society criteria to diagnose PPPD and studies that followed up participants for less than three months.  DATA COLLECTION AND ANALYSIS: We used standard Cochrane methods. Our primary outcomes were: 1) improvement in vestibular symptoms (assessed as a dichotomous outcome - improved or not improved), 2) change in vestibular symptoms (assessed as a continuous outcome, with a score on a numerical scale) and 3) serious adverse events. Our secondary outcomes were: 4) disease-specific health-related quality of life, 5) generic health-related quality of life and 6) other adverse effects. We considered outcomes reported at three time points: 3 to < 6 months, 6 to ≤ 12 months and > 12 months. We planned to use GRADE to assess the certainty of evidence for each outcome.  MAIN RESULTS: We identified no studies that met our inclusion criteria.

Authors' Conclusions

At present, there is no evidence from placebo-controlled randomised trials regarding pharmacological treatments - specifically SSRIs and SNRIs - for PPPD. Consequently, there is great uncertainty over the use of these treatments for this condition. Further work is needed to establish whether any treatments are effective at improving the symptoms of PPPD, and whether their use is associated with any adverse effects.

---

### Pharmacological interventions for persistent postural-perceptual dizziness (PPPD) [^290d551d]. The Cochrane Database of Systematic Reviews (2023). Medium credibility.

Abstract

Background

Persistent postural‐perceptual dizziness (PPPD) is a chronic balance disorder, which is characterised by subjective unsteadiness or dizziness that is worse on standing and with visual stimulation. The condition was only recently defined and therefore the prevalence is currently unknown. However, it is likely to include a considerable number of people with chronic balance problems. The symptoms can be debilitating and have a profound impact on quality of life. At present, little is known about the optimal way to treat this condition. A variety of medications may be used, as well as other treatments, such as vestibular rehabilitation.

Objectives

To evaluate the benefits and harms of pharmacological interventions for persistent postural‐perceptual dizziness (PPPD).

Search methods

The Cochrane ENT Information Specialist searched the Cochrane ENT Register; Central Register of Controlled Trials (CENTRAL); Ovid MEDLINE ; Ovid Embase; Web of Science; ClinicalTrials.gov; ICTRP and additional sources for published and unpublished trials. The date of the search was 21 November 2022.

Selection criteria

We included randomised controlled trials (RCTs) and quasi‐RCTs in adults with PPPD, which compared selective serotonin reuptake inhibitors (SSRIs) or serotonin and norepinephrine reuptake inhibitors (SNRIs) with either placebo or no treatment. We excluded studies that did not use the Bárány Society criteria to diagnose PPPD and studies that followed up participants for less than three months.

Data collection and analysis

We used standard Cochrane methods. Our primary outcomes were: 1) improvement in vestibular symptoms (assessed as a dichotomous outcome ‐ improved or not improved), 2) change in vestibular symptoms (assessed as a continuous outcome, with a score on a numerical scale) and 3) serious adverse events. Our secondary outcomes were: 4) disease‐specific health‐related quality of life, 5) generic health‐related quality of life and 6) other adverse effects. We considered outcomes reported at three time points: 3 to < 6 months, 6 to ≤ 12 months and > 12 months. We planned to use GRADE to assess the certainty of evidence for each outcome.

Main results

We identified no studies that met our inclusion criteria.

Authors' conclusions

At present, there is no evidence from placebo‐controlled randomised trials regarding pharmacological treatments ‐ specifically SSRIs and SNRIs ‐ for PPPD. Consequently, there is great uncertainty over the use of these treatments for this condition. Further work is needed to establish whether any treatments are effective at improving the symptoms of PPPD, and whether their use is associated with any adverse effects.

---

### Pharmacological interventions for persistent postural-perceptual dizziness (PPPD) [^ec153af2]. The Cochrane Database of Systematic Reviews (2023). Medium credibility.

Dealing with missing data

We did not identify any studies suitable for inclusion in this review, therefore we did not need to contact authors regarding missing data.

Assessment of heterogeneity

As no studies were included, we did not need to make an assessment of heterogeneity.

Assessment of reporting biases

See the protocol for more information on how we had planned to assess reporting bias (Webster 2022b).

Data synthesis

See the protocol for more information on how we had planned to synthesise the data (Webster 2022b).

Subgroup analysis and investigation of heterogeneity

If statistical heterogeneity was identified, we planned to assess this considering the following subgroups:

Different types of medication, within a specific class.
Different doses/frequency of administration.
Use of concomitant treatment.

Sensitivity analysis

See the protocol for more information on the sensitivity analyses that we had planned to conduct (Webster 2022b).

Summary of findings and assessment of the certainty of the evidence

We planned to use the GRADE approach to rate the overall certainty of evidence using GRADEpro GDT and the guidance in Chapter 14 of the Cochrane Handbook for Systematic Reviews of Interventions (Handbook 2021).

We have prepared a summary of findings table for the main comparison:

SSRIs and SNRIs versus placebo/no treatment.

We included the primary outcomes in the summary of findings table and prioritised outcomes at the time point 6 to ≤ 12 months.

---

### Pharmacological interventions for persistent postural-perceptual dizziness (PPPD) [^cac230b2]. The Cochrane Database of Systematic Reviews (2023). Medium credibility.

Summary of findings

Summary of findings 1 
SSRIs and SNRIs compared to placebo or no treatment for PPPD

---

### Pharmacological interventions for persistent postural-perceptual dizziness (PPPD) [^4822a0b0]. The Cochrane Database of Systematic Reviews (2023). Medium credibility.

Discussion

Summary of main results

No studies were included in this review.

Overall completeness and applicability of evidence

At present, there is no evidence from placebo‐controlled randomised controlled trials (RCTs) regarding the efficacy and harms of selective serotonin reuptake inhibitors (SSRIs) or serotonin and norepinephrine reuptake inhibitors (SNRIs) for persistent postural‐perceptual dizziness (PPPD).

Quality of the evidence

We planned to use GRADE to assess the certainty of the evidence for each of our outcomes. However, as we identified no studies for inclusion in this review we are not able to comment on the certainty of the evidence.

Potential biases in the review process

We adhered to our protocol during the review process. However, some decisions about relevant studies to include in this review may be subject to some debate. Firstly, we only included studies that compared SSRIs or SNRIs to a placebo or no treatment control group. This was because we did not consider there to be a 'gold standard' treatment available for PPPD. Therefore, to establish whether these interventions may be effective, we needed to compare them to no treatment, or ‐ ideally ‐ a placebo.

Secondly, we did not include any studies that followed up participants for less than three months. This was because we considered that the efficacy of an intervention in a chronic condition, such as PPPD, could not be judged with very short follow‐up. Even if an intervention is effective at one month or two months, it does not mean that there will be persisting efficacy in the long term. However, despite this restriction, we did not identify any studies that were excluded on the basis of this criterion. Therefore, we think it unlikely that the review would be different if studies with shorter follow‐up had been included.

Finally, in keeping with our protocol, we only included studies where participants had received a diagnosis of PPPD using the Bárány society criteria. This may have led to the omission of studies that predated these criteria and recruited participants with different ‐ but related ‐ diagnoses, such as chronic subjective dizziness or phobic postural vertigo. This could be regarded as a bias in the review process. Nonetheless, we considered it vital to focus the review on those people with a definitive diagnosis of PPPD, to assess the current evidence for this specific condition.

---

### Advances in diagnosis and treatment of vestibular migraine and the vestibular disorders it mimics [^6e6a783b]. Neurotherapeutics (2024). Medium credibility.

Persistent Postural-Perceptual Dizziness

In the 2010s, the Bárány society committee for the classification of vestibular disorders convened to better characterize similar disorders that had variably been referred to as phobic postural vertigo, chronic subjective dizziness, space motion discomfort, and visual vertigo. This resulted in the description of a single disease entity now known as persistent postural-perceptual dizziness (PPPD). Importantly, this condition is more common than the structural vestibular disorders such as Ménière's disease and bilateral vestibular loss. Thus, it is an important disorder for any clinician to be aware of when assessing dizzy patients.

In 2017, the Bárány society described the diagnostic criteria for PPPD. The major features of this disease include a sense of dizziness, unsteadiness, or non-spinning vertigo on most days, lasting at least hours each day, and ongoing for at least 3 months. The symptoms can occur spontaneously, however are exacerbated by upright posture, active or passive motion, and exposure to moving or complex visual stimuli. Typically, the disease is triggered by an event that causes dizziness or vertigo and occasionally other neurological, medical, or psychiatric illnesses. The disease often causes significant distress or functional impairment and is not better accounted for by another disorder. A thorough neurological examination is warranted prior to making this diagnosis since a chronic sense of unsteadiness can occur secondary to diseases such as peripheral neuropathy, cerebellar ataxia, myelopathy, and Parkinsonism.

The underlying pathophysiology of PPPD is complex and theorized to be related to anxiety-related responses to triggering events, alteration in control of posture and gait, a dependence on visual input, poor spatial navigation and memory, alterations in the activity of the vestibular and visual cortices and frontal lobes, and a misperception of movement. It is classified as a functional neurological disorder (FND), and like other FNDs, treatment involves patient education and counseling, psychotherapy, especially cognitive behavioral therapy (CBT), and treatment of co-existing anxiety and/or depression when present, vestibular rehabilitation, and medications. Although currently large scale randomized-controlled treatment trials for PPPD are lacking, there is evidence to suggest that selective seroronin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), or sometimes these medications in conjunction with benzodiazepines are effective for PPPD. Much of the evidence in favor of SSRIs and SNRIs comes from studies performed on the similar previously described disorders prior to the description of this disease.

---

### Anxiety disorders: a review [^b3e434db]. JAMA (2022). Excellent credibility.

Importance

Anxiety disorders have a lifetime prevalence of approximately 34% in the US, are often chronic, and significantly impair quality of life and functioning.

Observations

Anxiety disorders are characterized by symptoms that include worry, social and performance fears, unexpected and/or triggered panic attacks, anticipatory anxiety, and avoidance behaviors. Generalized anxiety disorder (6.2% lifetime prevalence), social anxiety disorder (13% lifetime prevalence), and panic disorder (5.2% lifetime prevalence) with or without agoraphobia are common anxiety disorders seen in primary care. Anxiety disorders are associated with physical symptoms, such as palpitations, shortness of breath, and dizziness. Brief screening measures applied in primary care, such as the Generalized Anxiety Disorder-7, can aid in diagnosis of anxiety disorders (sensitivity, 57.6% to 93.9%; specificity, 61% to 97%). Providing information about symptoms, diagnosis, and evidence-based treatments is a first step in helping patients with anxiety. First-line treatments include pharmacotherapy and psychotherapy. Selective serotonin reuptake inhibitors (SSRIs, eg, sertraline) and serotonin-norepinephrine reuptake inhibitors (SNRIs, eg, venlafaxine extended release) remain first-line pharmacotherapy for generalized anxiety disorder, social anxiety disorder, and panic disorder. Meta-analyses suggest that SSRIs and SNRIs are associated with small to medium effect sizes compared with placebo (eg, generalized anxiety disorder: standardized mean difference [SMD], -0.55 [95% CI, -0.64 to -0.46]; social anxiety disorder: SMD, -0.67 [95% CI, -0.76 to -0.58]; panic disorder: SMD, -0.30 [95% CI, -0.37 to -0.23]). Cognitive behavioral therapy is the psychotherapy with the most evidence of efficacy for anxiety disorders compared with psychological or pill placebo (eg, generalized anxiety disorder: Hedges g=1.01 [large effect size] [95% CI, 0.44 to 1.57]; social anxiety disorder: Hedges g=0.41 [small to medium effect] [95% CI, 0.25 to 0.57]; panic disorder: Hedges g=0.39 [small to medium effect[ [95% CI, 0.12 to 0.65]), including in primary care. When selecting treatment, clinicians should consider patient preference, current and prior treatments, medical and psychiatric comorbid illnesses, age, sex, and reproductive planning, as well as cost and access to care.

Conclusions and Relevance

Anxiety disorders affect approximately 34% of adults during their lifetime in the US and are associated with significant distress and impairment. First-line treatments for anxiety disorders include cognitive behavioral therapy, SSRIs such as sertraline, and SNRIs such as venlafaxine extended release.

---

### Current and emerging medical therapies for dizziness [^b90ba3fa]. Otolaryngologic Clinics of North America (2021). Medium credibility.

Medical therapies for dizziness are aimed at vertigo reduction, secondary symptom management, or the root cause of the pathologic process. Acute peripheral vertigo pharmacotherapies include antihistamines, calcium channel blockers, and benzodiazepines. Prophylactic pharmacotherapies vary between causes. For Meniere disease, betahistine and diuretics remain initial first-line oral options, whereas intratympanic steroids and intratympanic gentamicin are reserved for uncontrolled symptoms. For cerebellar dizziness and oculomotor disorders, 4-aminopyridine may provide benefit. For vestibular migraine, persistent postural perceptual dizziness and mal de débarquement, treatment options overlap and include selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, tricyclic antidepressants and calcium channel blockers.

---

### Vestibular migraine treatment: a comprehensive practical review [^e8d9ca80]. Brain (2022). Medium credibility.

Authors’ comments

Amitriptyline and venlafaxine may reduce vertigo severity and frequency to a similar degree as other medications, although like the majority of other treatments the evidence is primarily taken from before-and-after analyses. Venlafaxine is likely to have additional benefits in VM patients with concurrent low mood.

---

### Antidepressants and dizziness [^2b03593f]. Journal of Psychopharmacology (2006). Low credibility.

Despite several evidences supporting a close relationship between dizziness and anxiety symptoms, the role of antidepressants in the treatment of such conditions remains poorly explored. The high prevalence of dizziness during serotonin reuptake inhibitors discontinuation syndrome and the few reports suggesting efficacy of antidepressants in treating some vestibular disorders justify a careful investigation. Neurophysiologic studies suggest possible focus of investigation on mechanisms of drug action. Psychophysiologic studies also suggest a possible role of antidepressant drugs in improving balance control and cognitive functioning. Controlled studies involving antidepressants with selective action in different neurotransmitters systems are necessary to elucidate the complex pathophysiologic mechanisms involving emotional and balance control. For future researches, special attention must be paid to the methodology of balance evaluation and the interaction between posture control and cognitive functioning.

---

### Pharmacological agents for the prevention of vestibular migraine [^c0581c55]. The Cochrane Database of Systematic Reviews (2015). Low credibility.

Background

Vestibular migraine is a common cause of episodic vertigo. Many preventive treatments have been proposed for this condition, including calcium antagonists, beta-blockers, antidepressants, anticonvulsants, selective 5-HT1 agonists, serotonin antagonists and non-steroidal anti-inflammatory drugs (NSAIDs).

Objectives

To assess the effects of pharmacological agents for the prevention of vestibular migraine.

Search Methods

The Cochrane Ear, Nose and Throat Disorders Group (CENTDG) Trials Search Co-ordinator searched the CENTDG Trials Register; Central Register of Controlled Trials (CENTRAL 2015, Issue 5); PubMed; EMBASE; CINAHL; Web of Science; Clinicaltrials.gov; ICTRP and additional sources for published and unpublished trials. The date of the search was 5 June 2015.

Selection Criteria

Randomised controlled trials (RCTs) in adults (over 18 years) with a diagnosis of vestibular migraine orprobable vestibular migraine according to the Bárány Society/International Headache Society (IHS) criteria, treated in any setting, comparing pharmacological treatments used in the prevention of vestibular migraine, including beta-blockers, calcium antagonists, anticonvulsants, antidepressants, serotonin antagonists and non-steroidal anti-inflammatory drugs (NSAIDs) against placebo or no treatment.

Data Collection and Analysis

We used the standard methodological procedures expected by The Cochrane Collaboration.

Main Results

Our literature search identified 558 reports, however only 11 were sufficiently relevant for further assessment. We excluded two studies because they did not use the IHS diagnostic criteria for vestibular migraine. We excluded a further eight studies for various reasons related to their design (e.g. lack of placebo or no treatment comparator), aim (e.g. treatment of vestibular migraine rather than prevention) or conduct (e.g. early termination). We identified one ongoing study comparing metoprolol to placebo. The results of this study are awaited; recruitment of the last patient is expected by the end of 2016.

Authors' Conclusions

We found no evidence from RCTs to answer the question set out in the review objectives. This review has identified the need for well-designed randomised controlled trials to answer questions about the efficacy of current and new treatments.

---

### Vestibular migraine: the most frequent entity of episodic vertigo [^2a800f60]. Journal of Neurology (2016). Low credibility.

Less established medications in migraine treatment such as benzodiazepines, selective serotonin reuptake inhibitors (SSRI), pizotifen, dothiepin, acetazolamide, and behavioral modification including special diets were reported to have positive effects on VM. However, a clear therapeutic recommendation for the specific treatment of VM cannot be easily drawn from these data. Moreover, it must be taken into account that inconsistent definitions of VM were used in many of these studies especially in the older ones, so that the examined cohorts were quite heterogeneous. The new diagnostic criteria will eliminate this obvious shortcoming in the future and lead to more comparable, better quality studies.

Vestibular rehabilitation training proved effective in VM patients as add-on treatment to medical therapy or as a stand-alone treatment option. Thirty-six patients (VM = 20, vestibular impairment  = 16) with daily vestibular symptoms participated in a 9-week vestibular rehabilitation program. Each patient attended five therapy sessions over 6 months. While the VM group demonstrated poorer subjective performance at therapy onset, both groups benefitted equally from rehabilitation. The same degree of improvement was observed in the migraine group regardless of the medication regime. Thus, vestibular rehabilitation training may be effective in VM regardless of the medical prophylactic therapy used. This agrees with the well-known positive effect of physical activity on the reduction of migraine attack frequency. However, a study with a controlled design is still needed for VM.

The future perspectives of both clinical and basic science studies investigating the pathophysiological mechanisms of VM are promising. Understanding the neurochemical organization of the vestibular, nociceptive, and cognitive pathways and their interactions will provide realistic strategies for treatment of the disorder. Further research is needed to clarify the probable genetic mechanisms leading to greater susceptibility. Multicenter randomized controlled treatment trials based on pathophysiology must now be designed on the basis of the recently established diagnostic criteria.

---

### Clinical practice guideline: Ménière's disease [^b68c4541]. Otolaryngology--Head and Neck Surgery (2020). High credibility.

Ménière’s disease (MD) symptomatic management of vertigo—clinicians should offer a limited course of vestibular suppressants for management of vertigo only during MD attacks; this recommendation is supported by nonrandomized or historically controlled studies (case-control and observational), with aggregate evidence quality Grade C and medium confidence; benefits are better symptom control and improved QOL, whereas risks and costs include side effects (urinary retention, dry mouth, visual changes, sedation, addiction) and impaired vestibular compensation; overall, the benefit-harm assessment is a preponderance of benefit over harm, and value judgments note vertigo’s detrimental impact on QOL and patient preference for symptom relief.

---

### 2023 U.S. department of veterans affairs and U.S. department of defense clinical practice guideline for the management of headache [^466fe20e]. Annals of Internal Medicine (2024). High credibility.

VA/DoD Headache guideline—fluoxetine and venlafaxine for prevention states: There is insufficient evidence to recommend for or against fluoxetine or venlafaxine for the prevention of headache (Neither for nor against | Reviewed, Not changed). Evidence cited includes an SR of six RCTs of serotonin and norepinephrine reuptake inhibitors in which subjects treated with SNRIs (five venlafaxine, one duloxetine) were (n=202) versus placebo/active comparators (n=216); four studies (n=279) enrolled migraine and two (n=139) vestibular migraine. Patients given duloxetine had a reduction of 2 headache days versus placebo and venlafaxine 2–4 headache days versus placebo, but confidence in the quality of the evidence was very low, studies were very small with unclear risk of bias, and did not reflect the critical outcome of interest for migraine prophylaxis. Prior SRs found no evidence that SSRI or SNRI medications prevented migraine. Safety notes include a risk of serotonin syndrome with other serotonergic medications, a boxed warning for increased risk of suicidality in children, adolescents, and young adults, multiple adverse events including nausea, weight gain, dry mouth, sexual dysfunction, constipation, and for SNRIs increased blood pressure, and that tolerability to side effects is high and usually improves over time.

---

### Treatment of vertigo [^86eeb016]. American Family Physician (2005). Low credibility.

Vertigo is the illusion of motion, usually rotational motion. As patients age, vertigo becomes an increasingly common presenting complaint. The most common causes of this condition are benign paroxysmal positional vertigo, acute vestibular neuronitis or labyrinthitis, Ménière's disease, migraine, and anxiety disorders. Less common causes include vertebrobasilar ischemia and retrocochlear tumors. The distinction between peripheral and central vertigo usually can be made clinically and guides management decisions. Most patients with vertigo do not require extensive diagnostic testing and can be treated in the primary care setting. Benign paroxysmal positional vertigo usually improves with a canalith repositioning procedure. Acute vestibular neuronitis or labyrinthitis improves with initial stabilizing measures and a vestibular suppressant medication, followed by vestibular rehabilitation exercises. Meniere's disease often responds to the combination of a low-salt diet and diuretics. Vertiginous migraine headaches generally improve with dietary changes, a tricyclic antidepressant, and a beta blocker or calcium channel blocker. Vertigo associated with anxiety usually responds to a selective serotonin reuptake inhibitor.

---

### Guidelines for reasonable and appropriate care in the emergency department 3 (GRACE-3): acute dizziness and vertigo in the emergency department [^692f0554]. Academic Emergency Medicine (2023). High credibility.

Regarding medical management for dizziness and vertigo, more specifically with respect to management of vestibular neuritis, SAEM 2023 guidelines recommend to consider ensuring shared decision-making with patients to weigh the risks and benefits of short-term corticosteroid treatment in adult patients with a clinical diagnosis of vestibular neuritis presenting within 3 days of symptom onset.

---

### Pharmacological interventions for persistent postural-perceptual dizziness (PPPD) [^f9a7ac58]. The Cochrane Database of Systematic Reviews (2023). Medium credibility.

The pathophysiological processes underlying PPPD are incompletely understood, although a model has been proposed to explain the likely mechanism (Staab 2020). This suggests that temporary changes in balance function caused by a specific event (such as an acute balance disorder, medical or psychological disturbance) become chronic, despite the resolution of the initial insult. Balance function appears to become more dependent on visual input, and individuals may be hypervigilant with regard to their own movement and balance. PPPD may reflect a maladaptation to an acute vestibular insult.

The impact of PPPD on the individual may be considerable, due to the chronic and persistent nature of the condition, and the consequences it has for day‐to‐day activities and quality of life. A small qualitative study recently identified three themes describing the impact of this disorder on individuals (Sezier 2019). These were a perception that their symptoms were not viewed as part of a valid or credible disorder, a change in their perceived self‐identity since their symptoms started, and challenges in coping with the symptoms and changes in their lives.

Description of the intervention

In the absence of a good understanding of the pathophysiological mechanisms underlying PPPD, it is difficult to identify potential therapies based on any specific mechanisms. However, a variety of drugs and non‐drug interventions have been used in people with balance disorders characterised by similar symptoms, and these are therefore considered possible therapeutic options in people with PPPD.

A small number of pharmacological interventions have been used for the treatment of PPPD (Popkirov 2018 ; Staab 2020). Selective serotonin reuptake inhibitors (SSRIs) and serotonin‐norepinephrine reuptake inhibitors (SNRIs) are, at present, the most commonly used medications for this disorder. Both are more widely used for depression and anxiety disorders. They are administered as oral tablets, usually titrating the dose up from a low starting level to reach the therapeutic range. Both classes of drug have a slow onset of action and, for depressive disorders, it may take several weeks before any benefit is seen.

---

### Chronic dizziness and anxiety (...) [^148b3831]. JAMA Network (2005). Excellent credibility.

Patients Eighty-eight consecutive patients treated with an SSRI for CSD and anxiety between 1998 and 2003. All patients were referred for evaluation of unremitting dizziness. They entered SSRI treatment after comprehensive neurotologic and psychiatric evaluations revealed a syndrome of CSD with accompanying anxiety. Patients were separated into 3 groups according to their longitudinal patterns of illness: otogenic, defined as primary neurotologic conditions triggering secondary anxiety disorders; psychogenic, defined as anxiety disorders alone causing dizziness; and interactive, defined neurotologic conditions exacerbating preexisting anxiety. In 2 studies, 11, 12 we found that selective serotonin reuptake inhibitors were effective for patients with chronic dizziness and major or minor anxiety and depression. Similarly, Horii et al13 reported that the SSRI paroxetine hydrochloride reduced chronic dizziness and depression.

However, all patients did not respond equally well to treatment. The reasons for this excellent response are not entirely clear, because SSRIs are not typically used to treat the types of phobic symptoms most commonly seen in these patients. It is possible that their low-level anxiety symptoms responded to SSRI treatment, which indirectly improved their dizziness. However, the high percentage of patients with a complete remission of both dizziness and anxiety suggests that the SSRIs may have had a more direct effect on dizziness itself. Serotonin is present in the vestibular nuclei and affects the responsiveness of motion sensitive neural pathways from the vestibular nuclei through the inferior olive to the nodulus and flocculus of the cerebellum. 19, 20 These may be sites where SSRIs can directly decrease dizziness. This study found SSRIs to be effective for patients with CSD and anxiety, although not all patients responded equally well to treatment.

The magnitude of the therapeutic response depended on the longitudinal pattern of illness, which was determined from the clinical history obtained at the outset of the study. Patients with otogenic and psychogenic patterns had higher rates of complete remission of both dizziness and anxiety during SSRI treatment than did those with an interactive pattern. In contrast, patients in the interactive group were more likely to experience a partial reduction in symptoms rather than a complete remission. These results suggest that neurotologists and others who regularly treat patients with chronic dizziness can feel confident recommending SSRI treatment for patients with otogenic and psychogenic patterns of illness. Additional therapies may be needed for those with an interactive pattern of CSD and anxiety.

---

### Pharmacological interventions for acute attacks of vestibular migraine [^14bb66e7]. The Cochrane Database of Systematic Reviews (2023). Medium credibility.

Abstract

Background

Vestibular migraine is a form of migraine where one of the main features is recurrent attacks of vertigo. These episodes are often associated with other features of migraine, including headache and sensitivity to light or sound. The unpredictable and severe attacks of vertigo can lead to a considerable reduction in quality of life. The condition is estimated to affect just under 1% of the population, although many people remain undiagnosed. A number of pharmacological interventions have been used, or proposed to be used, at the time of a vestibular migraine attack to help reduce the severity or resolve the symptoms. These are predominantly based on treatments that are in use for headache migraine, with the belief that the underlying pathophysiology of these conditions is similar.

Objectives

To assess the benefits and harms of pharmacological interventions used to relieve acute attacks of vestibular migraine.

Search methods

The Cochrane ENT Information Specialist searched the Cochrane ENT Register; Central Register of Controlled Trials (CENTRAL); Ovid MEDLINE; Ovid Embase; Web of Science; ClinicalTrials.gov; ICTRP and additional sources for published and unpublished trials. The date of the search was 23 September 2022.

Selection criteria

We included randomised controlled trials (RCTs) and quasi‐RCTs in adults with definite or probable vestibular migraine comparing triptans, ergot alkaloids, dopamine antagonists, antihistamines, 5‐HT3 receptor antagonists, gepants (CGRP receptor antagonists), magnesium, paracetamol or non‐steroidal anti‐inflammatory drugs (NSAIDs) with either placebo or no treatment.

Data collection and analysis

We used standard Cochrane methods. Our primary outcomes were: 1) improvement in vertigo (assessed as a dichotomous outcome ‐ improved or not improved), 2) change in vertigo (assessed as a continuous outcome, with a score on a numerical scale) and 3) serious adverse events. Our secondary outcomes were: 4) disease‐specific health‐related quality of life, 5) improvement in headache, 6) improvement in other migrainous symptoms and 7) other adverse effects. We considered outcomes reported at three time points: < 2 hours, 2 to 12 hours, > 12 to 72 hours. We used GRADE to assess the certainty of evidence for each outcome.

Main results

We included two RCTs with a total of 133 participants, both of which compared the use of triptans to placebo for an acute attack of vestibular migraine. One study was a parallel‐group RCT (of 114 participants, 75% female). This compared the use of 10 mg rizatriptan to placebo. The second study was a smaller, cross‐over RCT (of 19 participants, 70% female). This compared the use of 2.5 mg zolmitriptan to placebo.

Triptans may result in little or no difference in the proportion of people whose vertigo improves at up to two hours after taking the medication. However, the evidence was very uncertain (risk ratio 0.84, 95% confidence interval 0.66 to 1.07; 2 studies; based on 262 attacks of vestibular migraine treated in 124 participants; very low‐certainty evidence). We did not identify any evidence on the change in vertigo using a continuous scale. Only one of the studies assessed serious adverse events. No events were noted in either group, but as the sample size was small we cannot be sure if there are risks associated with taking triptans for this condition (0/75 receiving triptans, 0/39 receiving placebo; 1 study; 114 participants; very low‐certainty evidence).

Authors' conclusions

The evidence for interventions used to treat acute attacks of vestibular migraine is very sparse. We identified only two studies, both of which assessed the use of triptans. We rated all the evidence as very low‐certainty, meaning that we have little confidence in the effect estimates and cannot be sure if triptans have any effect on the symptoms of vestibular migraine. Although we identified sparse information on potential harms of treatment in this review, the use of triptans for other conditions (such as headache migraine) is known to be associated with some adverse effects.

We did not identify any placebo‐controlled randomised trials for other interventions that may be used for this condition. Further research is needed to identify whether any interventions help to improve the symptoms of vestibular migraine attacks and to determine if there are side effects associated with their use.

---

### Clinical practice guideline: Ménière's disease [^6d1ed493]. Otolaryngology--Head and Neck Surgery (2020). High credibility.

Regarding medical management for Ménière's disease, more specifically with respect to acute therapy, AAO-HNS 2020 guidelines recommend to offer a limited course of vestibular suppressants for the management of acute vertigo attacks in patients with Ménière's disease.

---

### Pharmacological interventions for acute attacks of vestibular migraine [^8911636a]. The Cochrane Database of Systematic Reviews (2023). Medium credibility.

Background

Vestibular migraine is a form of migraine where one of the main features is recurrent attacks of vertigo. These episodes are often associated with other features of migraine, including headache and sensitivity to light or sound. The unpredictable and severe attacks of vertigo can lead to a considerable reduction in quality of life. The condition is estimated to affect just under 1% of the population, although many people remain undiagnosed. A number of pharmacological interventions have been used, or proposed to be used, at the time of a vestibular migraine attack to help reduce the severity or resolve the symptoms. These are predominantly based on treatments that are in use for headache migraine, with the belief that the underlying pathophysiology of these conditions is similar.  OBJECTIVES: To assess the benefits and harms of pharmacological interventions used to relieve acute attacks of vestibular migraine.

Search Methods

The Cochrane ENT Information Specialist searched the Cochrane ENT Register; Central Register of Controlled Trials (CENTRAL); Ovid MEDLINE; Ovid Embase; Web of Science; ClinicalTrials.gov; ICTRP and additional sources for published and unpublished trials. The date of the search was 23 September 2022.

Selection Criteria

We included randomised controlled trials (RCTs) and quasi-RCTs in adults with definite or probable vestibular migraine comparing triptans, ergot alkaloids, dopamine antagonists, antihistamines, 5-HT3 receptor antagonists, gepants (CGRP receptor antagonists), magnesium, paracetamol or non-steroidal anti-inflammatory drugs (NSAIDs) with either placebo or no treatment.  DATA COLLECTION AND ANALYSIS: We used standard Cochrane methods. Our primary outcomes were: 1) improvement in vertigo (assessed as a dichotomous outcome - improved or not improved), 2) change in vertigo (assessed as a continuous outcome, with a score on a numerical scale) and 3) serious adverse events. Our secondary outcomes were: 4) disease-specific health-related quality of life, 5) improvement in headache, 6) improvement in other migrainous symptoms and 7) other adverse effects. We considered outcomes reported at three time points: < 2 hours, 2 to 12 hours, > 12 to 72 hours. We used GRADE to assess the certainty of evidence for each outcome.  MAIN RESULTS: We included two RCTs with a total of 133 participants, both of which compared the use of triptans to placebo for an acute attack of vestibular migraine. One study was a parallel-group RCT (of 114 participants, 75% female). This compared the use of 10 mg rizatriptan to placebo. The second study was a smaller, cross-over RCT (of 19 participants, 70% female). This compared the use of 2.5 mg zolmitriptan to placebo.  Triptans may result in little or no difference in the proportion of people whose vertigo improves at up to two hours after taking the medication. However, the evidence was very uncertain (risk ratio 0.84, 95% confidence interval 0.66 to 1.07; 2 studies; based on 262 attacks of vestibular migraine treated in 124 participants; very low-certainty evidence). We did not identify any evidence on the change in vertigo using a continuous scale. Only one of the studies assessed serious adverse events. No events were noted in either group, but as the sample size was small we cannot be sure if there are risks associated with taking triptans for this condition (0/75 receiving triptans, 0/39 receiving placebo; 1 study; 114 participants; very low-certainty evidence).  AUTHORS' CONCLUSIONS: The evidence for interventions used to treat acute attacks of vestibular migraine is very sparse. We identified only two studies, both of which assessed the use of triptans. We rated all the evidence as very low-certainty, meaning that we have little confidence in the effect estimates and cannot be sure if triptans have any effect on the symptoms of vestibular migraine. Although we identified sparse information on potential harms of treatment in this review, the use of triptans for other conditions (such as headache migraine) is known to be associated with some adverse effects.  We did not identify any placebo-controlled randomised trials for other interventions that may be used for this condition. Further research is needed to identify whether any interventions help to improve the symptoms of vestibular migraine attacks and to determine if there are side effects associated with their use.

---

### Advances in diagnosis and treatment of vestibular migraine and the vestibular disorders it mimics [^17588af9]. Neurotherapeutics (2024). Medium credibility.

Traditional preventive therapies

While there is a paucity of randomized controlled trials for medical management of VM, extrapolation of data of preventive medications from migraine headache trials is reasonable, and a common practical treatment strategy for VM (see Table 2). Common classes of medications that have been used to treat migraine for years include antiepileptics such as topiramate and valproic acid, tricyclic antidepressants such as amitriptyline and nortriptyline, serotonin norepinephrine reuptake inhibitors (SNRIs) such as venlafaxine and duloxetine, beta blockers such as propranolol and metoprolol, and calcium channel blockers such as verapamil. Although there is a dearth of randomized controlled trials, there is evidence in the form of retrospective analyses to suggest the migraine preventive medications as a general class also work for VM. Several of these individual agents including propranolol, venlafaxine, nortriptyline, topiramate, metoprolol, and valproic acid have been individually studied and shown to be effective for VM. Finally, there is some evidence to suggest that medications such as acetazolamide and lamotrigine may be more effective for the vestibular symptoms than the headache symptoms in migraine patients. The choice of agent to initiate may be based on side effect profile versus its utility in treating coexisting conditions.

Table 2 
Vestibular migraine preventive pharmacologic options.

---

### Treatment of vestibular migraine: a systematic review and meta-analysis [^3a5b1fa7]. The Laryngoscope (2021). Medium credibility.

Objective

To assess the efficacy of the various therapies used for the prevention of vestibular migraine (VM).

Methods

Primary studies were identified though PubMed, Scopus, PsycINFO, and Cochrane Library by two independent investigators for articles published through April 2019. The search identified randomized comparison or observational studies pertaining to vestibular migraine treatment. Meta-analysis was performed on pre- and posttreatment Dizziness Handicap Inventory, vertigo frequency, and percentage of perceived improvement.

Results

Literature search identified 13 studies that reported sufficient outcome measures to be included in the analysis. Patients with VM had a mean age of 43.3years with female-to-male gender ratio of 2.1:1. Classes of therapeutic agents included antiepileptic drugs, calcium channel blockers, tricyclic antidepressants, β-blockers, serotonin and norepinephrine reuptake inhibitors, and vestibular rehabilitation. All treatment options that were analyzed demonstrated improvement in all of the outcome parameters, but due to significant heterogeneity and lack of standardized reporting on outcomes, establishment of preferred treatment modality could not be determined.

Conclusions

Various treatment modalities have been evaluated for preventative treatment of VM. Physician familiarity, patient comorbidities, and the side-effect profiles of various interventions likely influence the selection of intervention. Future randomized controlled trials with restrictive inclusion criteria and generalizable standardized outcome measures will allow for more robust meta-analyses and for more evidence-based treatment of vestibular migraines. Laryngoscope, 131:186-194, 2021.

---

### Advances in diagnosis and treatment of vestibular migraine and the vestibular disorders it mimics [^9d3a8fb6]. Neurotherapeutics (2024). Medium credibility.

A commonality between VM and PPPD is that both diseases may be triggered or exaggerated by passive motion (e.g. riding an escalator), visual stimuli (e.g. a bright computer screen), or complex visual cues (e.g. watching an action movie). Symptoms that are present more often than not and vary throughout the day (e.g. worse toward the end of the day) are suggestive of PPPD, whereas VM is an episodic condition lasting minutes, hours, or sometimes days in duration. Migraine specific associations such as headache or migraine triggers such as barometric pressure changes, menstruation, or specific foods may also make vestibular migraine more likely. Anxiety symptoms commonly coexist with both VM and PPPD.

VM and PPPD not only share certain clinical features (e.g. visual sensitivity), but also commonly co-exist. In these cases, treatment may focus on either disease. When treating a patient who has both VM and PPPD, it may be reasonable to treat with an SNRI such as venlafaxine or duloxetine since both have evidence in migraine as well as PPPD. Should this treatment fail, regular follow-ups to understand whether symptomatology is more VM or PPPD-related allows the clinician to tailor the treatment plan. If the patient has developed migraine triggers for symptoms and frequent headaches, migraine lifestyle modifications and a migraine preventive can be considered. Likewise, if the patient has developed constant symptoms that are worse when upright, then an SSRI and CBT may be considered.

---

### Evidence-based practice: management of vertigo [^6debb71d]. Otolaryngologic Clinics of North America (2012). Low credibility.

The article focuses on the evidence basis for the management of benign paroxysmal positional vertigo, the most common diagnosis of vertigo in both primary care and subspecialty settings. An overview is presented, along with evidence-based clinical assessment, diagnosis, and management. Summaries of differential diagnosis of vertigo and outcomes are presented.

---

### Pharmacological interventions for persistent postural-perceptual dizziness (PPPD) [^d115cc2f]. The Cochrane Database of Systematic Reviews (2023). Medium credibility.

Agreements and disagreements with other studies or reviews

There are few published reviews that consider the efficacy and harms of interventions for PPPD. We did not identify any other systematic reviews that addressed this question. However, we note the findings of a recent narrative review on this topic, which also highlights the lack of RCTs in this field (Staab 2020). Results from a single RCT were included in this article (Yu 2018). However, this considered a non‐pharmacological intervention (cognitive behavioural therapy) as an adjunct to sertraline treatment (an SSRI) for PPPD.

---

### Pharmacological interventions for prophylaxis of vestibular migraine [^04f75677]. The Cochrane Database of Systematic Reviews (2023). Medium credibility.

Primary outcomes

Improvement in vertigo Measured as a dichotomous outcome (improved/not improved), according to self‐report, or according to a change of a specified score (as described by the study authors) on a vertigo rating scale.
Change in vertigo Measured as a continuous outcome, to identify the extent of change in vertigo symptoms.
Serious adverse events Including any event that caused death, was life‐threatening, required hospitalisation, resulted in disability or permanent damage, or in congenital abnormality. Measured as the number of participants who experienced at least one serious adverse event during the follow‐up period.

Vertigo symptoms comprise a variety of different features, including frequency of episodes, duration of episodes and severity/intensity of the episodes. Where possible, we included data for the vertigo outcomes that encompassed all of these three aspects (frequency, duration and severity/intensity of symptoms). However, we anticipated that these data may not be available from all studies. If they were unavailable, then we extracted data on the frequency of vertigo episodes as an alternative measure for these outcomes.

---

### Clinical practice guideline: benign paroxysmal positional vertigo (update) [^70c3cdd7]. Otolaryngology--Head and Neck Surgery (2017). Medium credibility.

Regarding medical management for benign paroxysmal positional vertigo, more specifically with respect to vestibular suppressants, AAO-HNS 2017 guidelines recommend to do not use vestibular suppressant medications (such as antihistamines and/or benzodiazepines) routinely in patients with BPPV.

---

### Systemic pharmacological interventions for Ménière's disease [^70eb1975]. The Cochrane Database of Systematic Reviews (2023). Medium credibility.

Primary outcomes

Improvement in vertigo Measured as a dichotomous outcome (improved/not improved), according to self‐report, or according to a change of a specified score (as described by the study authors) on a vertigo rating scale.
Change in vertigo Measured as a continuous outcome, to identify the extent of change in vertigo symptoms.
Serious adverse events Including any event that causes death, is life‐threatening, requires hospitalisation, results in disability or permanent damage, or in congenital abnormality. Measured as the number of participants who experienced at least one serious adverse event during the follow‐up period.

Vertigo symptoms comprise a variety of different features, including frequency of episodes, duration of episodes and severity/intensity of the episodes. Where possible, we included data for the vertigo outcomes that encompassed all of these three aspects (frequency, duration and severity/intensity of symptoms). However, we anticipated that these data may not be available from all studies. We therefore extracted data on the frequency of vertigo episodes as an alternative measure for these outcomes.

---

### Vestibular migraine treatment: a comprehensive practical review [^1c167cbf]. Brain (2022). Medium credibility.

Tricyclics and serotonin–noradrenaline reuptake inhibitors

Despite being one of the more commonly used preventative treatments for migraine headache, there have been no dedicated studies of antidepressant medications in VM, and they have only been examined in small multiple-treatment-arm studies. Amitriptyline and other tricyclics, and venlafaxine, are thought to modulate endogenous pain mechanisms by inhibiting reuptake of serotonin and noradrenaline.There were two studies involving amitriptyline, one of nortriptyline and three of venlafaxine.

A retrospective before-and-after analysis of 13 patients treated with amitriptyline 25 mg daily found post-treatment improvements in vestibular symptoms (VAS 6.4–2.6, P = 0.001) and headache symptoms (VAS 7.5–2.8, P < 0.001) after 3 months.In a second study amitriptyline 10 mg daily was given for 5 weeks in 24 patients, and despite the low dose and short duration of treatment there were reductions in mean monthly vertigo frequency (17.5–5.4, no significance testing reported) and subjective vertigo and headache symptoms on a VAS.Side effects were common despite the low dose of 10 mg daily: xerostomia was reported in 67% and daytime somnolence in 61%. The rate of loss to follow-up and treatment non-adherence was also high in this study (only 16 of 24 patients were analysed), although this was also seen with other treatments and may thus be better explained by methodological issues rather than amitriptyline being less well tolerated than other medications.

---

### Non-pharmacological interventions for persistent postural-perceptual dizziness (PPPD) [^dbc895bd]. The Cochrane Database of Systematic Reviews (2023). Medium credibility.

Overall completeness and applicability of evidence

We identified only one study that was suitable for inclusion in this review, and this considered an intervention that ‐ to our knowledge ‐ is not in widespread use for PPPD (transcranial direct current stimulation). This study only considered some of our outcomes of interest, so the efficacy of this intervention for vestibular symptoms and generic quality of life is unknown. Data on adverse effects were also sparse, due to the small number of participants in this study. Furthermore, follow‐up was only conducted at three months, so we do not know if there are any longer‐term effects of this intervention. It should be noted that participants in both arms of this study also started treatment with a selective serotonin reuptake inhibitor (SSRI) at the time of enrolling in the trial. This may have affected the results, as any beneficial (or harmful) effects from medical treatment may mask any additional effects of the transcranial direct current stimulation.

Although we did identify a number of randomised controlled trials (RCTs) that aimed to assess the efficacy of interventions for PPPD, these were not suitable for inclusion in this review due to two major concerns. Firstly, a number of studies compared two different interventions, without the use of an appropriate placebo or 'no treatment' control group. For a relatively new diagnostic category, this is surprising. To establish a 'gold standard' treatment for PPPD, we must first be certain that any effects seen are better than no treatment, and this requires assessment in a randomised trial.

A second issue seen with the studies that we did identify is the relatively short duration of follow‐up. A small number of RCTs were found that compared an active intervention to no treatment for PPPD, but the follow‐up time was only four to eight weeks. For a chronic condition, we considered this duration of follow‐up to be insufficient. A short‐term change in symptoms may not accurately reflect the efficacy of these treatments over a longer time period, and therefore is unlikely to be helpful when weighing up different treatment options.

Quality of the evidence

We assessed the certainty of the evidence using the GRADE approach. Overall, we rated the certainty of the evidence as very low for all outcomes. This was due to the small numbers of participants in the trial (only 24 people), leading to wide confidence intervals, and imprecision in the overall effect estimates.

---

### Pharmacological interventions for prophylaxis of vestibular migraine [^313dbbd1]. The Cochrane Database of Systematic Reviews (2023). Medium credibility.

Abstract

Background

Vestibular migraine is a form of migraine where one of the main features is recurrent attacks of vertigo. These episodes are often associated with other features of migraine, including headache and sensitivity to light or sound. These unpredictable and severe attacks of vertigo can lead to a considerable reduction in quality of life. The condition is estimated to affect just under 1% of the population, although many people remain undiagnosed. A number of pharmacological interventions have been used or proposed to be used as prophylaxis for this condition, to help reduce the frequency of the attacks. These are predominantly based on treatments that are in use for headache migraine, with the belief that the underlying pathophysiology of these conditions is similar.

Objectives

To assess the benefits and harms of pharmacological treatments used for prophylaxis of vestibular migraine.

Search methods

The Cochrane ENT Information Specialist searched the Cochrane ENT Register; Central Register of Controlled Trials (CENTRAL); Ovid MEDLINE; Ovid Embase; Web of Science; ClinicalTrials.gov; ICTRP and additional sources for published and unpublished trials. The date of the search was 23 September 2022.

Selection criteria

We included randomised controlled trials (RCTs) and quasi‐RCTs in adults with definite or probable vestibular migraine comparing beta‐blockers, calcium channel blockers, antiepileptics, antidepressants, diuretics, monoclonal antibodies against calcitonin gene‐related peptide (or its receptor), botulinum toxin or hormonal modification with either placebo or no treatment. We excluded studies with a cross‐over design, unless data from the first phase of the study could be identified.

Data collection and analysis

We used standard Cochrane methods. Our primary outcomes were: 1) improvement in vertigo (assessed as a dichotomous outcome ‐ improved or not improved), 2) change in vertigo (assessed as a continuous outcome, with a score on a numerical scale) and 3) serious adverse events. Our secondary outcomes were: 4) disease‐specific health‐related quality of life, 5) improvement in headache, 6) improvement in other migrainous symptoms and 7) other adverse effects. We considered outcomes reported at three time points: < 3 months, 3 to < 6 months, > 6 to 12 months. We used GRADE to assess the certainty of evidence for each outcome.

Main results

We included three studies with a total of 209 participants. One evaluated beta‐blockers and the other two evaluated calcium channel blockers. We did not identify any evidence for the remaining interventions of interest.

Beta‐blockers versus placebo

One study (including 130 participants, 61% female) evaluated the use of 95 mg metoprolol once daily for six months, compared to placebo. The proportion of people who reported improvement in vertigo was not assessed in this study. Some data were reported on the frequency of vertigo attacks at six months and the occurrence of serious adverse effects. However, this is a single, small study and for all outcomes the certainty of evidence was low or very low. We are unable to draw meaningful conclusions from the numerical results.

Calcium channel blockers versus no treatment

Two studies, which included a total of 79 participants (72% female), assessed the use of 10 mg flunarizine once daily for three months, compared to no intervention. All of the evidence for this comparison was of very low certainty. Most of our outcomes were only reported by a single study, therefore we were unable to conduct any meta‐analysis. Some data were reported on improvement in vertigo and change in vertigo, but no information was available regarding serious adverse events. We are unable to draw meaningful conclusions from the numerical results, as these data come from single, small studies and the certainty of the evidence was very low.

Authors' conclusions

There is very limited evidence from placebo‐controlled randomised trials regarding the efficacy and potential harms of pharmacological interventions for prophylaxis of vestibular migraine. We only identified evidence for two of our interventions of interest (beta‐blockers and calcium channel blockers) and all evidence was of low or very low certainty. Further research is necessary to identify whether these treatments are effective at improving symptoms and whether there are any harms associated with their use.

---

### Pharmacological interventions for prophylaxis of vestibular migraine [^f1caff38]. The Cochrane Database of Systematic Reviews (2023). Medium credibility.

Background

Vestibular migraine is a form of migraine where one of the main features is recurrent attacks of vertigo. These episodes are often associated with other features of migraine, including headache and sensitivity to light or sound. These unpredictable and severe attacks of vertigo can lead to a considerable reduction in quality of life. The condition is estimated to affect just under 1% of the population, although many people remain undiagnosed. A number of pharmacological interventions have been used or proposed to be used as prophylaxis for this condition, to help reduce the frequency of the attacks. These are predominantly based on treatments that are in use for headache migraine, with the belief that the underlying pathophysiology of these conditions is similar.

Objectives

To assess the benefits and harms of pharmacological treatments used for prophylaxis of vestibular migraine.

Search Methods

The Cochrane ENT Information Specialist searched the Cochrane ENT Register; Central Register of Controlled Trials (CENTRAL); Ovid MEDLINE; Ovid Embase; Web of Science; ClinicalTrials.gov; ICTRP and additional sources for published and unpublished trials. The date of the search was 23 September 2022.

Selection Criteria

We included randomised controlled trials (RCTs) and quasi-RCTs in adults with definite or probable vestibular migraine comparing beta-blockers, calcium channel blockers, antiepileptics, antidepressants, diuretics, monoclonal antibodies against calcitonin gene-related peptide (or its receptor), botulinum toxin or hormonal modification with either placebo or no treatment. We excluded studies with a cross-over design, unless data from the first phase of the study could be identified.

Data Collection and Analysis

We used standard Cochrane methods. Our primary outcomes were: 1) improvement in vertigo (assessed as a dichotomous outcome - improved or not improved), 2) change in vertigo (assessed as a continuous outcome, with a score on a numerical scale) and 3) serious adverse events. Our secondary outcomes were: 4) disease-specific health-related quality of life, 5) improvement in headache, 6) improvement in other migrainous symptoms and 7) other adverse effects. We considered outcomes reported at three time points: < 3 months, 3 to < 6 months, > 6 to 12 months. We used GRADE to assess the certainty of evidence for each outcome.

Main Results

We included three studies with a total of 209 participants. One evaluated beta-blockers and the other two evaluated calcium channel blockers. We did not identify any evidence for the remaining interventions of interest. Beta-blockers versus placebo One study (including 130 participants, 61% female) evaluated the use of 95 mg metoprolol once daily for six months, compared to placebo. The proportion of people who reported improvement in vertigo was not assessed in this study. Some data were reported on the frequency of vertigo attacks at six months and the occurrence of serious adverse effects. However, this is a single, small study and for all outcomes the certainty of evidence was low or very low. We are unable to draw meaningful conclusions from the numerical results. Calcium channel blockers versus no treatment Two studies, which included a total of 79 participants (72% female), assessed the use of 10 mg flunarizine once daily for three months, compared to no intervention. All of the evidence for this comparison was of very low certainty. Most of our outcomes were only reported by a single study, therefore we were unable to conduct any meta-analysis. Some data were reported on improvement in vertigo and change in vertigo, but no information was available regarding serious adverse events. We are unable to draw meaningful conclusions from the numerical results, as these data come from single, small studies and the certainty of the evidence was very low.

Authors Conclusions

There is very limited evidence from placebo-controlled randomised trials regarding the efficacy and potential harms of pharmacological interventions for prophylaxis of vestibular migraine. We only identified evidence for two of our interventions of interest (beta-blockers and calcium channel blockers) and all evidence was of low or very low certainty. Further research is necessary to identify whether these treatments are effective at improving symptoms and whether there are any harms associated with their use.

---

### Venlafaxine hydrochloride, extended release [^c4437c17]. FDA (2024). Medium credibility.

5.5 Discontinuation of Treatment with Venlafaxine Hydrochloride Extended-Release Tablets

Discontinuation symptoms have been systematically evaluated in patients taking venlafaxine, to include prospective analyses of clinical trials and retrospective surveys of trials in major depressive disorder and social anxiety disorder. Abrupt discontinuation or dose reduction of venlafaxine at various doses has been found to be associated with the appearance of new symptoms, the frequency of which increased with increased dose level and with longer duration of treatment. Reported symptoms include agitation, anorexia, anxiety, confusion, impaired coordination and balance, diarrhea, dizziness, dry mouth, dysphoric mood, fasciculation, fatigue, headaches, hypomania, insomnia, nausea, nervousness, nightmares, sensory disturbances (including shock-like electrical sensations), somnolence, sweating, tremor, vertigo, and vomiting.

During marketing of venlafaxine hydrochloride extended-release capsules, other SNRIs (Serotonin and Norepinephrine Reuptake Inhibitors), and SSRIs (Selective Serotonin Reuptake Inhibitors), there have been spontaneous reports of adverse reactions occurring upon discontinuation of these drugs, particularly when abrupt, including the following: dysphoric mood, irritability, agitation, dizziness, sensory disturbances (e.g. paresthesias such as electric shock sensations), anxiety, confusion, headache, lethargy, emotional lability, insomnia, hypomania, tinnitus, and seizures. While these reactions are generally self-limiting, there have been reports of serious discontinuation symptoms.

Patients should be monitored for these symptoms when discontinuing treatment with Venlafaxine Hydrochloride Extended-Release Tablets. A gradual reduction in the dose rather than abrupt cessation is recommended whenever possible. If intolerable symptoms occur following a decrease in the dose or upon discontinuation of treatment, then resuming the previously prescribed dose may be considered. Subsequently, the physician may continue decreasing the dose, but at a more gradual rate [see Dosage and Administration (2.4)] .

---

### Vestibular migraine treatment: a comprehensive practical review [^7c517a7d]. Brain (2022). Medium credibility.

My patient has VM—what should I do?

The evidence from studies included in this review is of almost universally low quality, making interpretation complex; however, this does not necessarily imply lack of treatment effect. Treatment recommendations (Box 1) summarize the available evidence both in terms of efficacy but also side-effect profile. It seems prudent to highlight that, as for any condition, one should not treat ‘vestibular migraine’ but rather the patient, and thus an individualized approach may be necessary, considering both the clinical and demographic features, but also psychological variables that commonly coexist in this (and any other) chronic disorder. The sometimes violent and almost always disconcerting and incapacitating loss of control that is associated with unpredictable vertiginous attacks renders this latter point of particular importance. Such an individualized treatment approach that nevertheless utilizes available evidence to fit the particular person can maximize patient acceptance of treatment as well as the chance of a positive response. Examples of real-life scenarios are given in Box 2 and Box 3.

Box 1 
Treatment options for management of vestibular migraine based on efficacy and side-effect profile data

All patients

Abortive treatment — use less than 10 days per month

Simple analgesics/NSAIDs/triptans for headache
Vestibular sedatives (cyclizine, prochlorperazine, cinnarizine) for vertigo
Consider prochlorperazine, cyclizine, cinnarizine, or domperidone for nausea

Preventative treatment — best efficacy evidence and lower rates of serious unwanted effects

Tricyclics (amitriptyline, nortriptyline)—consider if comorbid pain or insomnia.

Start 10 mg at night and titrate up in 10 mg increments every 1–2 weeks. Usual dose range 10–150 mg at night. Lower doses are often effective for VM symptoms; higher doses (≥75 mg) may benefit patients with anxiety/depression, although in our experience patients with VM rarely tolerate this much.

---

### Clinical practice guideline: benign paroxysmal positional vertigo (update) [^dbf3cd66]. Otolaryngology--Head and Neck Surgery (2017). Medium credibility.

AAO-HNSF guideline update—evidence sources and selection criteria are summarized as follows: The final data set retained was 20 systematic reviews or meta-analyses that met inclusion criteria, and the initial search for randomized controlled trials (RCTs) identified 38 RCTs with a total final data set of 27 RCTs that met inclusion criteria. Quality criteria for including reviews required relevance to the guideline topic, clear objective and methodology, explicit search strategy, and valid data extraction methods, while RCTs required relevance to the topic, publication in a peer-reviewed journal, and clear methodology with randomized allocation to treatment groups.

---

### Efficacy of a serotonin-norepinephrine reuptake inhibitor as a treatment for meniere disease: a randomized clinical trial [^aaeff042]. JAMA Otolaryngology-- Head & Neck Surgery (2024). High credibility.

Importance

Meniere disease accounts for up to 15% of new vestibular diagnoses,; however, the optimal treatment has yet to be identified. A conservative treatment that would reduce or stop the vertigo episodes has not been identified.

Objective

To determine the efficacy of a serotonin-norepinephrine reuptake inhibitor, venlafaxine, compared to placebo in treating patients with Meniere disease.

Design, Setting, and Participants

This was a randomized, double-blind, placebo-controlled, crossover pilot study spanning 22 weeks of follow-up. The clinical trial took place at a single-center tertiary referral center in Charleston, South Carolina. Participants were eligible if they were 18 years or older, had definite Meniere disease criteria as defined by Barany criteria, had at least 2 episodes in the last month, had not received intratympanic gentamycin, skull base surgery, or radiation therapy to the head or neck, not currently taking diuretics for Meniere disease, not currently taking oral steroids, and not currently taking serotonin-modulating medication. Patients were enrolled between February 2020 and September 2023.

Interventions

Patients received either 1 venlafaxine tablet, 37.5 mg, taken daily by mouth for 8 weeks or 1 placebo tablet taken daily by mouth for 8 weeks. Group 1 received placebo during phase 1 of the trial and venlafaxine in phase 2 of the trial. Group 2 received venlafaxine during phase 1 of the trial and placebo in phase 2 of the trial.

Main Outcomes and Measures

The main outcomes included the number of episodes and scores on the following scales: Dizziness Handicap Inventory, Neuropsychological Vertigo Inventory, Meniere Disease Patient-Oriented Symptom Index, 20-Item Short Form Health Survey, Penn State Worry Questionnaire, Cognitive Failure Questionnaire.

Results

A total of 182 patients were screened, and 40 participants with Meniere disease enrolled in the trial. The mean (SD) age of participants was 56.6 (14.3) years, and 22 (55%) were female. Participants had a mean (SD) of 13.8 (10.1) episodes per phase at baseline, 5.4 (4.4) episodes (Δ8.4) during the venlafaxine phase, and 5.0 (4.6) episodes (Δ8.8) during the placebo phase. No significant difference was identified between venlafaxine and placebo groups in the number of episodes or quality-of-life metrics.

Conclusions and Relevance

This randomized clinical trial failed to identify a difference between venlafaxine and placebo in number of episodes and other quality-of-life metrics. Future studies may benefit from different dosing regimens, larger cohorts, and longer lengths of therapy.

Trial Registration

ClinicalTrials.gov Identifier: NCT04218123.

---

### Serotonin reuptake inhibitors for dizziness with psychiatric symptoms (...) [^79090828]. JAMA Network (2002). Excellent credibility.

Conclusions Treatment with SSRIs relieved dizziness in patients with major or minor psychiatric symptoms, including those with peripheral vestibular conditions and migraine headaches. Patients fared far better with SSRI treatment than with treatment with vestibular suppressants or benzodiazepines. Despite these advantages, there were several concerns about prescribing SSRIs for patients with dizziness. Nausea is one of the most common adverse effects of all 5 SSRIs. It occurs at least transiently in about 20% of patients and is a leading cause of medication discontinuation. Dizziness is reported in up to 8% of patients taking an SSRI. 14 Other adverse effects, such as physical fatigue and mental sluggishness, might mimic symptoms that accompany chronic dizziness. The CGI-I scale was used dichotomously in this study. Scores were based on the change in severity of both dizziness and psychiatric symptoms from the initial evaluation to 20 weeks after the initiation of an SSRI therapy.

We treated 28 patients for at least 1 year and rated them a second time, comparing their clinical status at 12 months with that at 20 weeks. The results of the present study indicate that SSRI therapy can alleviate symptoms of dizziness in patients with major or minor anxiety disorders and major depression, whether these psychiatric conditions are the sole causes of patients' complaints or coexist with certain medical illnesses. Treatment with SSRIs also may be helpful for patients who experience chronic sensations of disequilibrium alone. Approximately two thirds of all patients who took an SSRI had a positive response, but those with psychiatric disorders alone, as well as those with psychiatric symptoms accompanied by peripheral vestibular deficits or migraine headaches, had the best outcomes. Patients with central nervous system illnesses, such as traumatic brain injury or stroke, fared poorly.

Treatment with SSRIs was effective in patients with many years of disability, although individuals with a shorter duration of illness had a more robust response than those who had been ill for a longer time. The initial data on long-term outcomes were encouraging. Nearly all patients who were followed up for 12 months or more enjoyed sustained benefits. Finally, the patient population in this study was similar to those described in investigations of psychogenic dizziness, 3 phobic postural vertigo, 4, 5 and space-motion phobia, 7 suggesting that SSRI therapy may benefit patients with those syndromes.

---

### Efficacy and safety of SSRIs, SNRIs, and placebo in children and adolescents (...) [^fdcc101e]. JAMA Network (2017). Excellent credibility.

Thirty-six trials were eligible, including 6778 participants; 17 studies for DD, 10 for AD, 8 for OCD, and 1 for PTSD. Analysis showed that SSRIs and SNRIs were significantly more beneficial compared with placebo, yielding a small effect size. Conclusions and Relevance Compared with placebo, SSRIs and SNRIs are more beneficial than placebo in children and adolescents; however, the benefit is small and disorder specific, yielding a larger drug-placebo difference for AD than for other conditions. Response to placebo is large, especially in DD. Severe adverse events are significantly more common with SSRIs and SNRIs than placebo.

Selective serotonin reuptake inhibitors are first-line pharmaceutical treatments for these disorders, whereas serotonin-norepinephrine reuptake inhibitors are considered second- or third-line treatments, given the limited available trial data to support their use. 3 This meta-analysis compares the differential efficacy of these drugs across the disorders for which they are primarily prescribed in a pediatric population and also assesses differences in response to placebo and in adverse events. Since the release of fluoxetine hydrochloride in the mid-1980s, the number of SSRIs and SNRIs has grown substantially. No significant differences in TEAEs or SAEs were found between SSRIs and SNRIs. The RRs for TEAEs stratified by drug and disorder are displayed in Table 1. Discontinuation of treatment due to adverse events was significantly more common in the antidepressant group compared with the placebo group.

Our meta-analysis addresses the response and safety profile of SNRIs, SSRIs, and placebo in pediatric DD, AD, OCD, and PTSD. Results indicate that SSRIs and SNRIs are more beneficial than placebo in treating these commonly diagnosed conditions in children and adolescents. However, the overall drug-placebo difference is small and varies significantly by disorder, with a larger response in AD than DD, especially for SSRIs.

---

### Comparative efficacy and safety of selective serotonin reuptake inhibitors and serotonin-norepinephrine reuptake inhibitors in older adults: a network meta-analysis [^31801708]. Journal of the American Geriatrics Society (2015). Low credibility.

Objectives

To establish the comparative efficacy and safety of selective serotonin reuptake inhibitors and serotonin-norepinephrine reuptake inhibitors in older adults using the network meta-analysis approach.

Design

Systematic review and network meta-analysis.

Participants

Individuals aged 60 and older.

Measurements

Data on partial response (defined as at least 50% reduction in depression score from baseline) and safety (dizziness, vertigo, syncope, falls, loss of consciousness) were extracted. A Bayesian network meta-analysis was performed on the efficacy and safety outcomes, and relative risks (RRs) with 95% credible intervals (CrIs) were produced.

Results

Fifteen randomized controlled trials were eligible for inclusion in the analysis. Citalopram, escitalopram, paroxetine, duloxetine, venlafaxine, fluoxetine, and sertraline were represented. Reporting on partial response and dizziness was sufficient to conduct a network meta-analysis. Reporting on other outcomes was sparse. For partial response, sertraline (RR=1.28), paroxetine (RR=1.48), and duloxetine (RR=1.62) were significantly better than placebo. The remaining interventions yielded RRs lower than 1.20. For dizziness, duloxetine (RR=3.18) and venlafaxine (RR=2.94) were statistically significantly worse than placebo. Compared with placebo, sertraline had the lowest RR for dizziness (1.14) and fluoxetine the second lowest (1.31). Citalopram, escitalopram, and paroxetine all had RRs between 1.4 and 1.7.

Conclusion

There was clear evidence of the effectiveness of sertraline, paroxetine, and duloxetine. There also appears to be a hierarchy of safety associated with the different antidepressants, although there appears to be a dearth of reporting of safety outcomes.

---

### Venlafaxine [^66e975d5]. FDA (2025). Medium credibility.

General

Discontinuation of Treatment with venlafaxine tablets

Discontinuation symptoms have been systematically evaluated in patients taking venlafaxine, to include prospective analyses of clinical trials in Generalized Anxiety Disorder and retrospective surveys of trials in major depressive disorder. Abrupt discontinuation or dose reduction of venlafaxine at various doses has been found to be associated with the appearance of new symptoms, the frequency of which increased with increased dose level and with longer duration of treatment. Reported symptoms include agitation, anorexia, anxiety, confusion, impaired coordination and balance, diarrhea, dizziness, dry mouth, dysphoric mood, fasciculation, fatigue, flu-like symptoms, headaches, hypomania, insomnia, nausea, nervousness, nightmares, sensory disturbances (including shock-like electrical sensations), somnolence, sweating, tremor, vertigo, and vomiting.

During marketing of venlafaxine tablets, other SNRIs (Serotonin and Norepinephrine Reuptake Inhibitors), and SSRIs (Selective Serotonin Reuptake Inhibitors), there have been spontaneous reports of adverse events occurring upon discontinuation of these drugs, particularly when abrupt, including the following: dysphoric mood, irritability, agitation, dizziness, sensory disturbances (e.g. paresthesias such as electric shock sensations), anxiety, confusion, headache, lethargy, emotional lability, insomnia, hypomania, tinnitus, and seizures. While these events are generally self-limiting, there have been reports of serious discontinuation symptoms.

---

### Clinical practice guideline: Ménière's disease [^a441e4b7]. Otolaryngology--Head and Neck Surgery (2020). High credibility.

Ménière’s disease—oral medications benefit–harm and policy framing: Benefits include improved vertigo control and improved quality of life (QOL); risks and costs include cost of therapy, side effects of medications, and promotion of ineffective therapy; the benefit–harm assessment is a balance of benefits and harm; value judgments note different practice patterns without a specific preference for one agent; the role of patient preferences is large; exclusions include patients with comorbid conditions making these medications contraindicated (ie, renal or cardiac disease, asthma) and allergies or sensitivities; the policy level is Option with no differences of opinion noted.

---

### Venlafaxine hydrochloride (venlafaxine) [^eadc80e2]. FDA (2025). Medium credibility.

Discontinuation of Treatment with Venlafaxine Hydrochloride

Discontinuation symptoms have been systematically evaluated in patients taking venlafaxine, to include prospective analyses of clinical trials in Generalized Anxiety Disorder and retrospective surveys of trials in major depressive disorder. Abrupt discontinuation or dose reduction of venlafaxine at various doses has been found to be associated with the appearance of new symptoms, the frequency of which increased with increased dose level and with longer duration of treatment. Reported symptoms include agitation, anorexia, anxiety, confusion, impaired coordination and balance, diarrhea, dizziness, dry mouth, dysphoric mood, fasciculation, fatigue, flu-like symptoms, headaches, hypomania, insomnia, nausea, nervousness, nightmares, sensory disturbances (including shock-like electrical sensations), somnolence, sweating, tremor, vertigo, and vomiting.

During marketing of venlafaxine hydrochloride, other SNRIs (Serotonin and Norepinephrine Reuptake Inhibitors), and SSRIs (Selective Serotonin Reuptake Inhibitors), there have been spontaneous reports of adverse events occurring upon discontinuation of these drugs, particularly when abrupt, including the following: dysphoric mood, irritability, agitation, dizziness, sensory disturbances (e.g., paresthesias such as electric shock sensations), anxiety, confusion, headache, lethargy, emotional lability, insomnia, hypomania, tinnitus, and seizures. While these events are generally self-limiting, there have been reports of serious discontinuation symptoms.

Patients should be monitored for these symptoms when discontinuing treatment with venlafaxine hydrochloride. A gradual reduction in the dose rather than abrupt cessation is recommended whenever possible. If intolerable symptoms occur following a decrease in the dose or upon discontinuation of treatment, then resuming the previously prescribed dose may be considered. Subsequently, the physician may continue decreasing the dose but at a more gradual rate (see DOSAGE AND ADMINISTRATION).

Anxiety and Insomnia

Treatment-emergent anxiety, nervousness, and insomnia were more commonly reported for venlafaxine-treated patients compared to placebo-treated patients in a pooled analysis of short-term, double-blind, placebo-controlled depression studies:

Anxiety, nervousness, and insomnia led to drug discontinuation in 2%, 2%, and 3%, respectively, of the patients treated with venlafaxine in the Phase 2 and Phase 3 depression studies.

---

### Pharmacological interventions for prophylaxis of vestibular migraine [^b84f87c9]. The Cochrane Database of Systematic Reviews (2023). Medium credibility.

Overall completeness and applicability of evidence

We only identified three studies that were eligible for inclusion in this review, and they evaluated just two of the interventions of interest. No placebo‐controlled randomised controlled trials (RCTs) were identified that considered other interventions which have been used, or proposed for use, in people with vestibular migraine. This includes antiepileptics, antidepressants, diuretics, monoclonal antibodies to calcitonin gene‐related peptide (CGRP) or its receptor, botulinum toxin and hormonal treatment.

Two of the studies included in this review enrolled participants who were experiencing at least two attacks of vestibular migraine per month. Therefore, most of the evidence here may relate to individuals who have relatively frequent attacks, and may not apply to those who experience less frequent episodes. We note that vestibular and headache symptoms may vary considerably between different individuals, and may also fluctuate over time. In addition, follow‐up for all included studies was for between three and six months, so we do not have any evidence regarding longer‐term follow‐up. The limited data available also meant that we were unable to conduct any subgroup analysis, so the relative efficacy and harms of these interventions in different subgroups of people with vestibular migraine is uncertain.

We did identify some evidence for most of our pre‐specified outcomes of interest in this review. However, no evidence was identified regarding associated migrainous symptoms (other than headache or vertigo), including photophobia, phonophobia, nausea and vomiting and visual aura. We also found only very limited information on potential adverse effects of these interventions.

We noted that the description of outcome measures was sometimes inadequate in the studies ‐ it was difficult to identify how outcomes were assessed and whether this was appropriate. For example, the study Yuan 2016 reported on 'improvement' in vertigo frequency, but did not provide a clear description of how vertigo was judged to have improved. The study Lepcha 2014 considered improvement in vertigo using an ordinal scoring system, which did not appear to have been validated for use. In addition, a fairly arbitrary cut‐off was used to separate those who had 'marked improvement' from those who had 'little improvement'. The use of different tools for measuring symptoms of vestibular migraine makes it difficult to pool results across studies. In addition, many of these tools do not appear to have been subject to rigorous assessment and validation for measuring symptoms of vestibular migraine. Therefore it is difficult to know whether they accurately estimate the change in symptoms with treatment.

---

### Pharmacological interventions for acute attacks of vestibular migraine [^c81eeffa]. The Cochrane Database of Systematic Reviews (2023). Medium credibility.

We also did not identify any randomised controlled trials (RCTs) that compared other interventions (as listed in Types of interventions) to either placebo or no treatment. Therefore, we do not have any information on the efficacy or harms of any other medications used to treat acute attacks of vestibular migraine.

Both studies used the same method to assess improvement in symptoms ‐ the change in a four‐point scale of symptom severity was converted to a dichotomous outcome (where "improvement" meant a change from severity of 3 or 2 down to 0 or 1). We could not find any information on whether this scale has been validated for used in this context. However, we note that some people may also regard a change in symptoms from 'severe' to 'moderate' as improvement. More work is needed to identify the best ways to measure symptoms of vestibular migraine, and assess what change in symptoms is meaningful and important to people with this condition.

For the outcome 'improvement in vertigo', people with 'mild' attacks of vestibular migraine were not included. Only attacks classed as moderate or severe were assessed for improvement. In addition, one of the included studies allowed participants to treat up to three attacks of vestibular migraine with the same medication (NCT02447991). Consequently, people who suffered more frequent attacks of vestibular migraine will have contributed more outcome data to the analysis than those who suffered only one attack over the course of the trial. The overall effect of these study features means that the outcome data may be skewed towards the effect for people with more severe or frequent attacks of vestibular migraine. As a consequence, the results may not be applicable to those with less frequent, or less severe attacks.

Triptans are widely used to treat headache migraine, where there is stronger evidence of their efficacy (Derry 2014b), in contrast to the results of this review of their use in vestibular migraine. It is unclear whether this is because the underlying pathophysiology of the two conditions may differ, or simply because the studies of vestibular migraine are too small or inadequately designed to detect an effect of triptans.

---

### Clinical practice guideline: benign paroxysmal positional vertigo (update) [^d4e18be6]. Otolaryngology--Head and Neck Surgery (2017). Medium credibility.

Benign paroxysmal positional vertigo (BPPV)—adverse effects and risks of vestibular suppressants: Conversely, vestibular suppressant medications have the potential for significant harm, and all of these medications may produce drowsiness, cognitive deficits, and interference with driving or operating machinery. Medications used for vestibular suppression, especially psychotropic medications such as benzodiazepines, are a significant independent risk factor for falls, the risk of falls increases in patients taking multiple medications and with the use of medications such as antidepressants, and the potential for polypharmacy when adding vestibular suppressants further exposes the elderly to additional risk. Benzodiazepines and antihistamines interfere with central compensation for a vestibular injury, the use of vestibular suppressants may obscure the findings on the Dix-Hallpike maneuvers, and there is evidence of additional potential harm from the antihistamine class of medications on cognitive functioning and on gastrointestinal motility, urinary retention, vision, and dry mouth in the elderly.

---

### Vestibular migraine: a critical review of treatment trials [^2a563541]. Journal of Neurology (2009). Low credibility.

Vestibular migraine (VM), also known as migraine-associated vertigo, is a common cause of dizziness in adults. We performed a comprehensive literature search regarding treatment for VM or migraine-associated vertigo during the period of 1990-2008 and used, individually or in combination, the search terms VM, migraine-associated vertigo, migraine-associated dizziness, migrainous vertigo, migraine and vertigo, migraine and disequilibrium, and headache and vertigo. We found nine publications that address treatment strategies for VM. One small randomized clinical trial found some benefit from the use of zolmitriptan for abortive treatment of VM. The other eight observational studies showed marginal improvement with migraine prophylactic medications such as nortriptyline, verapamil, or metoprolol. Until more specific treatment options become available, patients with VM need to be managed with similar prophylactic and abortive strategies as those used for migraine in adults.

---

### Clinical practice guideline: benign paroxysmal positional vertigo (update) [^e2ae1cb6]. Otolaryngology--Head and Neck Surgery (2017). Medium credibility.

Other disorders and medication effects that can resemble BPPV include psychiatric and pharmacologic causes. Patients with panic or anxiety disorders may complain of symptoms of light‑headedness and dizziness, and other studies have shown high prevalence of vestibular dysfunction for these patients. Several medications such as Mysoline, carbamazepine, phenytoin, sedatives, and antihypertensive and cardiovascular medications may produce side effects of dizziness and/or vertigo and should be considered in the differential diagnosis.

---

### The INVEST trial: a randomised feasibility trial of psychologically informed vestibular rehabilitation versus current gold standard physiotherapy for people with persistent postural perceptual dizziness [^736063fa]. Journal of Neurology (2022). Medium credibility.

Introduction

Persistent Postural Perceptual Dizziness (PPPD) is a complex functional neuro-vestibular disorder characterised by persistent dizziness, non-spinning vertigo and/or unsteadiness. It is thought to be a long-term maladaptation to neuro-otological, neurological or medical illness, and/or psychological distress. Since its international classification by the Bárány Society, PPPD is increasingly recognised as the single most common vestibular syndrome in specialised outpatient clinics and likely represents the vast majority of patients referred to vestibular rehabilitation. People living with PPPD have poor quality of life, severe dizziness handicap and an elevated risk of anxiety and depression.

Tailored treatment strategies have been recommended, including pharmacotherapy with selective serotonin reuptake inhibitors (SSRI), physiotherapy (vestibular rehabilitation) and cognitive-behavioural therapy (CBT), but there is a lack of prospective, randomised controlled trials or information on prognosis or outcomes. Vestibular rehabilitation therapy (VRT) is an established exercise-based treatment for people with structural vestibular disorders that is usually recommended for people with PPPD. However, the exercises must be carefully graded to avoid intolerable symptom provocation and psychological factors are known to negatively affect outcome. There is limited evidence in favour of CBT in PPPD, although one study reported short-term relief. However, there are better results when CBT is adapted to target illness-specific factors such as anxiety-related postural behaviour. There are also promising multidisciplinary programs, but these can be costly and difficult to replicate. Due to their similarities, there has been a desire to combine CBT and VRT for a long time, but no theory-driven, evidence-based intervention with a standardised treatment manual currently exists. To date there are only a few case reports and pilot studies [,–,]. Moreover, previous trials do not test interventions against current best practice.

---

### A prospective trial of sertraline for chronic subjective dizziness [^16728840]. The Laryngoscope (2004). Low credibility.

Objectives/Hypothesis

The authors previously reported that selective serotonin reuptake inhibitors (SSRIs) reduce chronic subjective dizziness in patients with and without psychiatric illnesses. To extend those preliminary findings and test the hypothesis that SSRIs may offer a novel treatment for chronic subjective dizziness, the authors conducted a prospective study of sertraline in patients with dizziness for more than 6 months, in the absence of active physical neurotologic illness.

Study Design

Sixteen-week, prospective, open-label, flexible-dose clinical trial.

Methods

Twenty-four patients with subjective dizziness for more than 6 months and no active physical neurotologic illness were studied. Eighteen patients had major anxiety disorders. Six had minor frustration or worry that did not warrant a psychiatric diagnosis. Sertraline was administered at a daily dose of 25 mg, which was increased to a maximum daily dose of 200 mg. Dizziness, functional impairment, and psychological distress were measured using the Dizziness Handicap Inventory (DHI) and Brief Symptom Inventory-53 (BSI-53). Treatment outcomes were analyzed using repeated-measures multivariate analyses of variance, with last observations carried forward.

Results

Three patients were excluded from data analysis for disqualifying medical conditions, one for protocol violations. Fifteen (75%) patients completed treatment. Five (25%) withdrew for adverse effects or lack of efficacy. The median daily dose of sertraline was 100 mg. Sertraline significantly reduced scores on all three DHI subscales and the BSI-53. Eleven of 15 (73%) patients who completed treatment had a positive response, including 8 of 11 (73%) with major anxiety disorders and 3 of 4 (75%) with no psychopathological conditions. Six patients enjoyed a full remission of symptoms.

Conclusion

Sertraline significantly reduced chronic subjective dizziness in patients without active physical neurotologic illness, including those with and without psychiatric comorbidity.

---

### Pharmacological interventions for acute attacks of vestibular migraine [^32b04cd4]. The Cochrane Database of Systematic Reviews (2023). Medium credibility.

How the intervention might work

For many of these interventions, the precise mechanism of action is uncertain. However, the use of these medications for headache migraine attacks has resulted in their uptake for vestibular migraine. Interventions may target the underlying processes that are thought to trigger vestibular migraine, or treat the associated symptoms, including headache, nausea and vomiting.

Triptans are commonly used as a treatment for headache migraine. They act as agonists at serotonergic 5HT1B/D receptors. Their effects include vasoconstriction of intracranial vessels, as well as altering the release of other neurotransmitters, which may interrupt the early pathways involved in a migraine attack (Tepper 2002).

Ergot alkaloids (such as dihydroergotamine or ergotamine) were the first specific anti‐migraine therapy available. Ergot alkaloids target serotonergic receptors, but unlike triptans they also affect dopamine and norepinephrine receptors (reviewed in Tfelt‐Hansen 2000 and Bigal 2003). With the emergence of the triptans, ergot alkaloids are used less often in the treatment of migraine.

Dopamine antagonists have been suggested to have some efficacy in treating acute attacks of migraine, but it is not clear whether this is dependent on their effects on dopamine receptors, or due to some other mechanism (reviewed in Akerman 2007).

Antihistamines have been used for their well‐known antiemetic and anti‐vertiginous properties. They are widely used for management of acute vestibular disorders (Hunter 2022). 5‐HT3 receptor antagonists are also primarily used for their anti‐emetic effects.

CGRP is a neurotransmitter found in numerous locations within the central nervous system and peripheral sensory nerves. Levels of this neurotransmitter have been found to be elevated during headache migraine episodes (Goadsby 1990), and to decrease with the use of triptans (Goadsby 1993). Gepants are novel molecules that target the calcitonin gene‐related peptide receptor, and are increasingly used for headache migraine (reviewed in Moreno‐Ajona 2020).

Magnesium has also been suggested to be of benefit in acute headache migraine episodes (Bigal 2002), although the mechanism of action is unclear.

A variety of analgesics have been used for migraine attacks, including paracetamol and NSAIDs. They may be effective for headache symptoms, but it is uncertain whether they have any benefit for vestibular symptoms. Caffeine is sometimes used in conjunction with analgesics to promote pain relief (Derry 2014a). As well as their analgesic properties, NSAIDs may have additional effects on the underlying pathophysiology of migraine (reviewed in Pardutz 2010).

---

### Clinical practice guideline: benign paroxysmal positional vertigo (update) [^fb84c489]. Otolaryngology--Head and Neck Surgery (2017). Medium credibility.

Vestibular migraine—prevalence and diagnostic criteria: It is very common, with a lifetime prevalence of 3.2%, and may account for as many as 14% of cases of vertigo. Diagnostic criteria include the following: ≥5 episodes of vestibular symptoms lasting 5 minutes to 72 hours, current or history of migraine according to International Headache Society Criteria, ≥1 migraine symptoms during at least 50% of the dizzy episodes, and other causes ruled out by appropriate investigations.

---

### Vestibular migraine treatment: a comprehensive practical review [^8b7415d0]. Brain (2022). Medium credibility.

The aforementioned study by Dornhoffer et al. included 18 patients treated with nortriptyline 20–50 mg daily and 17 patients treated with venlafaxine 37.5–75 mg daily. As discussed earlier, treatment duration was variable, some patients were treated with additional medications or vestibular rehabilitation and only patients who were compliant with medication were analysed. Mean DHI reduced by 16.8 points in the nortriptyline patients and 26.0 points in the venlafaxine patients (both reported as not statistically significant). Venlafaxine 37.5–150 mg daily was compared with propranolol 40–160 mg daily in an unblinded RCT of 64 patients.The Beck Depression Inventory (BDI) improved to a greater degree with venlafaxine (P = 0.002); however, there were no significant differences between the two groups for the BAI or vertigo outcome measures. A before-and-after analysis of the venlafaxine group showed improvements in mean monthly vertigo frequency (12.2–2.6, P < 0.001), DHI (50.9–19.9, P < 0.001) and subjective vertigo severity (VAS 7.9–1.8, P < 0.01) after 4 months, similar to the improvements seen with propranolol. In another study, 75 patients were systematically allocated 3 months of treatment with low-dose (37.5 mg daily) venlafaxine, flunarizine (10 mg daily) or sodium valproate (500 mg twice daily).A before-and-after analysis of the venlafaxine group showed a reduction in mean monthly vertigo frequency (5.8–3.1, P = 0), VAS vertigo severity (6.0–3.8, P = 0) and total DHI (41.7–31.3, P = 0.001) after treatment. Like the previous study which found superiority of venlafaxine for depressive symptoms, the emotional domain of the DHI improved to a greater degree with venlafaxine compared to the other treatments (P < 0.05). Tolerability of venlafaxine was comparable to the other treatments: discontinuation rate was 13% with venlafaxine and 12% with propranolol in one studyand 22% of patients reported side effects (with none discontinuing treatment) in the other, which was similar to the other medications.It should be noted that a withdrawal syndrome with venlafaxine can complicate its use clinically.

---

### Venlafaxine (venlafaxine hydrochloride) [^e144467a]. FDA (2025). Medium credibility.

5.5 Discontinuation of Treatment with Venlafaxine Extended-Release Tablets

Discontinuation symptoms have been systematically evaluated in patients taking venlafaxine, to include prospective analyses of clinical trials and retrospective surveys of trials in major depressive disorder and social anxiety disorder. Abrupt discontinuation or dose reduction of venlafaxine at various doses has been found to be associated with the appearance of new symptoms, the frequency of which increased with increased dose level and with longer duration of treatment. Reported symptoms include agitation, anorexia, anxiety, confusion, impaired coordination and balance, diarrhea, dizziness, dry mouth, dysphoric mood, fasciculation, fatigue, headaches, hypomania, insomnia, nausea, nervousness, nightmares, sensory disturbances (including shock-like electrical sensations), somnolence, sweating, tremor, vertigo, and vomiting.

During marketing of venlafaxine hydrochloride extended-release capsules, other SNRI's (Serotonin and Norepinephrine Reuptake Inhibitors), and SSRI's (Selective Serotonin Reuptake Inhibitors), there have been spontaneous reports of adverse reactions occurring upon discontinuation of these drugs, particularly when abrupt, including the following: dysphoric mood, irritability, agitation, dizziness, sensory disturbances (e.g. paresthesias such as electric shock sensations), anxiety, confusion, headache, lethargy, emotional lability, insomnia, hypomania, tinnitus, and seizures. While these reactions are generally self-limiting, there have been reports of serious discontinuation symptoms.

Patients should be monitored for these symptoms when discontinuing treatment with venlafaxine extended-release tablets. A gradual reduction in the dose rather than abrupt cessation is recommended whenever possible. If intolerable symptoms occur following a decrease in the dose or upon discontinuation of treatment, then resuming the previously prescribed dose may be considered. Subsequently, the physician may continue decreasing the dose but at a more gradual rate [see Dosage and Administration (2.4)].

---

### Clinical practice guideline: benign paroxysmal positional vertigo (update) [^9f25ee06]. Otolaryngology--Head and Neck Surgery (2017). Medium credibility.

Benign paroxysmal positional vertigo (BPPV) outcome assessment—Clinicians should reassess patients within 1 month after an initial period of observation or treatment to document resolution or persistence of symptoms, with the policy level designated as Recommendation. The action statement profile characterizes aggregate evidence quality as Grade C and the level of confidence in evidence as Medium, notes the role of patient preferences as Small, and reports no exceptions. Intentional vagueness clarifies that reassessment may include phone calls or other methods to document outcome, and the benefits-harm assessment indicates a preponderance of benefit over harm.

---

### Vestibular migraine treatment: a comprehensive practical review [^a60e4419]. Brain (2022). Medium credibility.

The main preventative treatment options include flunarizine, propranolol, tricyclics, sodium valproate, low-dose topiramate (25 mg twice daily) and venlafaxine, which have all shown benefit in before-and-after analyses in VM and are established treatments for migraine headache.

Flunarizine 10 mg daily is the only treatment that has demonstrated benefit (for vertigo frequency and symptom severity) compared to a control group, albeit without a placebo and in a study with significant methodological flaws.While not meeting criteria for inclusion in this review, a service evaluation of flunarizine use at our institution found that 90% of patients experienced symptomatic improvement, and although side effects were common (reported by 50%), most patients felt that these were outweighed by the clinical benefit.In our experience flunarizine is generally well tolerated; however, we recommend that patients receive long-term monitoring due to the risk of parkinsonism with prolonged use.Propranolol is also generally well-tolerated, and while there are no randomized studies, there are a number of supportive observational studies and we have certainly found it to be useful in some patients with VM. Amitriptyline was found to be beneficial in two before-and-after studies. While the small study involving nortriptyline did not find a statistically significant reduction in DHI,a number of studies not meeting criteria for inclusion in the review have reported some benefit,, and our experience is that nortriptyline is of similar effectiveness to amitriptyline and can also be used. Tricyclics may be useful in VM patients with comorbid insomnia even at low doses (10–25 mg daily); if used at higher doses they may also benefit patients with comorbid depression or anxiety, although high doses may lead to increased side effects. Sodium valproate may be effective in some patients; however, it can cause weight gain and is essentially contraindicated in women of childbearing potential, which significantly limits its use in the VM population. Topiramate, like other newer antiepileptic medications (e.g. levetiracetam and tiagabine), has been associated with a high frequency of depressive symptoms in clinical trials and may also increase the risk of self-harm or suicidal behaviour,thus should be used with caution in those with low mood or a history of depression. Topiramate is also teratogenic and should be avoided in women of childbearing age unless using reliable contraception. It may, however, be a good option in obese patients, as it can cause weight loss. Venlafaxine may be a good option if low mood is a significant comorbidity; however, it carries a risk of a withdrawal syndrome and patients should be counselled appropriately. Hypertension is another recognized side effect of venlafaxine therapy that appears to be dose-dependent, but its incidence tends to be low and the effect on blood pressure relatively weak,, although a case of hypertensive encephalopathy following venlafaxine has been reported.Lamotrigine is not a standard treatment for migraine and there has only been one very small study in VM,thus we recommend that it is considered only in patients who have failed multiple other options. In refractory patients the angiotensin receptor blocker candesartan or nutraceuticals (riboflavin, magnesium and coenzyme-Q10 alone or in combination) can be considered, although there are no studies in VM—this is justified by the fact that these treatments are well-tolerated, low risk and have evidence for benefit in migraine headache.The evidence for botulinum toxin to treat vestibular symptoms is currently very limited and somewhat conflicting, thus currently best suited to VM patients with prominent headache, as from the current evidence it appears to be less effective for vestibular symptoms.Additionally, it is expensive and may not be widely available: in the UK, botulinum toxin is funded for chronic migraine after failure of at least three other preventative treatments; however, it is not funded for VM. A single-centre analysis of CGRP inhibitors (not included in this review due to not meeting inclusion criteria) found that 60% of patients with VM retrospectively reported improvement in vestibular symptoms.While there is insufficient evidence to recommend CGRP inhibitors for VM, these may become an option in the future, and the results of a clinical trial comparing galcanezumab to placeboare eagerly awaited. We do not recommend acetazolamide because it is not a standard migraine treatment and is generally poorly tolerated,, and we do not recommend metoprolol due to the lack of demonstrable benefit against a placebo.

---

### Vestibular migraine treatment: a comprehensive practical review [^c191ed3d]. Brain (2022). Medium credibility.

Preventative treatment

Details of the 23 studies on prophylactic treatment are contained in Supplementary Table 2.

Pharmacological treatment

---

### Paroxetine, a selective serotonin reuptake inhibitor, reduces depressive symptoms and subjective handicaps in patients with dizziness [^9bfa05cf]. Otology & Neurotology (2004). Low credibility.

Objective and Study Design

When treating dizzy patients, the psychiatric aspect should be carefully addressed regardless of whether a well-defined organic disease is present. In this prospective study, we aimed to elucidate the role of paroxetine, a selective serotonin reuptake inhibitor, in the treatment of dizziness.

Setting and Patients

Forty-seven patients who complained of dizziness were treated with 20 mg of paroxetine per day. The depressive state of the patient was evaluated by the Zung Self-Rating Depression Scale (SDS). Treatment outcomes were measured with self-assessment of subjective handicaps in daily life using a dizziness and unsteadiness questionnaire. The questionnaire consisted of five factors related to emotional or bodily dysfunction that could be affected by dizziness. Changes in Self-Rating Depression Scale scores and subjective handicaps were assessed at 4 and 8 weeks after the start of paroxetine.

Results

In patients having well-defined organic diseases with high Self-Rating Depression Scale scores, paroxetine improved all five subjective handicap factors as well as Self-Rating Depression Scale scores. The decline in Self-Rating Depression Scale scores showed a significant correlation with improvement of subjective handicaps, which was related to emotional problems but not factors related to bodily dysfunction. Paroxetine was also effective for an improvement of factors related to emotional problems and Self-Rating Depression Scale scores in patients not having organic diseases but with high Self-Rating Depression Scale scores. In patients either with or without organic diseases with low Self-Rating Depression Scale scores, paroxetine had no effect on any subjective handicap factors and Self-Rating Depression Scale scores.

Conclusion

In the treatment of dizzy patients, paroxetine was effective at relieving subjective handicaps caused by dizziness, specifically, in patients with high Self-Rating Depression Scale scores.

---

### Venlafaxine hydrochloride (Effexor) [^e8a56549]. FDA (2023). Medium credibility.

5.7	Discontinuation Syndrome

Discontinuation symptoms have been systematically evaluated in patients taking venlafaxine, including prospective analyses of clinical studies in GAD and retrospective surveys of studies in MDD and SAD. Abrupt discontinuation or dose reduction of venlafaxine at various doses has been found to be associated with the appearance of new symptoms, the frequency of which increased with increased dose level and with longer duration of treatment. Reported symptoms include agitation, anorexia, anxiety, confusion, impaired coordination and balance, diarrhea, dizziness, dry mouth, dysphoric mood, fasciculation, fatigue, flu-like symptoms, headaches, hypomania, insomnia, nausea, nervousness, nightmares, sensory disturbances (including shock‑like electrical sensations), somnolence, sweating, tremor, vertigo, and vomiting.

There have been postmarketing reports of serious discontinuation symptoms which can be protracted and severe. Completed suicide, suicidal thoughts, aggression and violent behavior have been observed in patients during reduction in Effexor XR dosage, including during discontinuation. Other postmarketing reports describe visual changes (such as blurred vision or trouble focusing) and increased blood pressure after stopping or reducing the dose of Effexor XR.

During marketing of Effexor XR, other SNRIs, and SSRIs, there have been reports of adverse events occurring upon discontinuation of these drugs, particularly when abrupt, including the following: irritability, lethargy, emotional lability, tinnitus, and seizures.

Patients should be monitored for these symptoms when discontinuing treatment with Effexor XR. A gradual reduction in the dose, rather than abrupt cessation, is recommended. If intolerable symptoms occur following a decrease in the dose or upon discontinuation of treatment, then resuming the previously prescribed dose may be considered. Subsequently, the healthcare provider may continue decreasing the dose, but at a more gradual rate. In some patients, discontinuation may need to occur over a period of several months [see Dosage and Administration (2.10)] .

5.8	Seizures

Cases of seizure have been reported with venlafaxine therapy. Effexor XR has not been systematically evaluated in patients with seizure disorder. Effexor XR should be prescribed with caution in patients with a seizure disorder.

---

### Assessing the synergistic effectiveness of intermittent theta burst stimulation and the vestibular ocular reflex rehabilitation protocol in the treatment of mal de debarquement syndrome: a randomised controlled trial [^0c0e5415]. Journal of Neurology (2024). Medium credibility.

Introduction

Mal de Debarquement Syndrome (MdDS) is a rare central vestibular disorder characterised by a constant sensation of non-spinning vertigo (i.e. rocking, swaying, and bobbing). These motion sensations are commonly accompanied by a range of symptoms such as imbalance, ‘brain fog’, visual induced dizziness, sensitivity to light and sounds, anxiety, depression, and migraine. MdDS is typically triggered by exposure to passive motion, like that experienced on a boat, airplane, or motor vehicle. While some degree of non-spinning vertigo is common and transient following such experiences (termed Mal de Debarquement), a diagnosis of the chronic form, MdDS, requires symptoms to persist for at least one month. Not all onsets of MdDS can be attributed to a passive motion event, and a small subset of patients associate the onset of their symptoms to non-motion events, such as intense stress, sickness, or childbirth, and some individuals cannot identify any triggering event at all. The differing onset types have been classified as motion-triggered (MT) and non-motion-triggered (NMT) MdDS, respectively [–,,]. The MdDS clinical population demonstrates a female/male ratio of between 8:2 and 9:1. In females, the age of MdDS onset is commonly between 40 and 50 years, whereas male exhibits greater variability in age of onset. Previously, poor diagnostic criteria and lack of understanding of the condition in the medical community resulted in a high rate of misdiagnosed or undiagnosed patients. Though more recent diagnostic guidelines have become available, diagnosis is still complicated by an overlapping of symptoms with other vestibular pathologies, such as persistent postural perceptual dizziness and vestibular migraine. The underlying pathogenesis of MdDS is unknown, which limits treatment options. Currently, standard care for people with MdDS is benzodiazapines and other anti-anxiety or anti-depressant medications, such as selective serotonin reuptake inhibitors. Unfortunately, the effectiveness of these medications is mixed, from no reduction to only moderate reduction of symptoms, and none are considered to be curative. Another drawback of these types of medications is their potential for addiction and the development of tolerance, limiting prolonged usage. Other non-specific treatments, such as standard vestibular rehabilitation, chiropractic treatments, vestibular suppressants, and counselling, have been trialed with no substantial benefits.

---

### Clinical practice guideline: Ménière's disease [^fe9c9863]. Otolaryngology--Head and Neck Surgery (2020). High credibility.

Statement 16. Patient outcomes—Clinicians should document resolution, improvement, or worsening of vertigo, tinnitus, and hearing loss and any change in quality of life in patients with Ménière’s disease after treatment. Recommendation based on the controlled arms of RCTs, outcomes from RCTs, cohort studies, and observational studies with a preponderance of benefit over harm. Quality improvement opportunity is that tracking outcomes of therapy provides an opportunity for modification of management to optimize outcomes. Aggregate evidence quality is Grade C; level of confidence in evidence is Medium due to Grade C evidence. Benefits are opportunity to adjust for more effective therapy, possibility of more accurate diagnosis, opportunity for hearing rehabilitation, and patient engagement; risks, harms, and costs are cost and time of visits. Benefit-harm assessment is preponderance of benefit over harms; policy level is Recommendation. Intentional vagueness is that the word symptoms can refer to vertigo, hearing loss, tinnitus, or pressure depending on what is of most concern to the patient; the role of patient preferences is Medium, as some patients with subjectively adequate disease control may choose not to follow up.

---

### Pharmacological interventions for prophylaxis of vestibular migraine [^99399ef9]. The Cochrane Database of Systematic Reviews (2023). Medium credibility.

Agreements and disagreements with other studies or reviews

A previous Cochrane Review was prepared on this topic in 2016 but no studies were included (Maldonado Fernández 2015). At the time of publication for the previous review, the studies Bayer 2019 and Yuan 2016 had not been completed. The study Lepcha 2014 was also excluded from the original Cochrane Review, as the study used the Neuhauser 2001 criteria for diagnosis of vestibular migraine, rather than the International Headache Society (IHS) criteria. We considered that these two sets of diagnostic criteria were sufficiently similar that studies using either should be included in the review.

We identified a recent systematic review that assessed the use of a number of different pharmacological interventions for vestibular migraine (antiepileptic drugs, calcium channel blockers, tricyclic antidepressants, beta‐blockers, serotonin and norepinephrine reuptake inhibitors), as well as vestibular rehabilitation (Byun 2021). This review differs from our own in two important ways. Firstly, the authors included non‐randomised studies as well as RCTs. In addition, meta‐analyses were conducted using data collected before and after treatment for all studies. Therefore, the comparison between randomised groups was not maintained (even when analysing data from RCTs) and the studies were analysed as if they were non‐comparative cohort studies. In this review, many of these treatments appeared to show efficacy for improvement in the frequency of vestibular migraine attacks, reduction (improvement) in Dizziness Handicap Inventory (DHI) scores and overall improvement in symptoms. However, there was no comparison with an appropriate control group for any of these analyses, therefore it is not possible to comment on how much of this improvement was related to the intervention itself. Given the fluctuation in symptoms of vestibular migraine we considered that these data may not accurately reflect the efficacy of these treatments. Nonetheless, Byun 2021 and colleagues do draw some similar conclusions to our own review, including the need for a longer duration of follow‐up, and the overall paucity of evidence from randomised controlled trials.

Another recent systematic review evaluated the use of pharmacological (and non‐pharmacological) interventions for both the prophylaxis and acute treatment of vestibular migraine (Smyth 2022). Again, the authors of this review included both randomised and non‐randomised studies, therefore the results are not directly comparable with our own review. However, again the conclusions are similar ‐ that the overall evidence base for the treatment of vestibular migraine is of low certainty, and that well‐designed clinical trials are required in this area.

---

### VA / DoD clinical practice guideline for management of posttraumatic stress disorder and acute stress disorder [^bdef2532]. DoD/VA (2023). High credibility.

Appendix B: Pharmacotherapy—antidepressants monotherapy dosing for posttraumatic stress disorder (PTSD) lists dosing and key safety points. Paroxetine immediate release (IR) is initiated at 10–20 mg daily and controlled release (CR) at 12.5 mg daily, with dose ranges of 20–50 mg daily and 12.5–50 mg. Sertraline is initiated at 25–50 mg daily with a 50–200 mg daily range. Venlafaxine IR starts at 25 mg 2 or 3 times a day and extended release (XR) at 37.5 mg daily, with dose ranges of 75–375 mg in 2–3 divided doses and 75–300 mg once daily. All antidepressants have a Black Box warning for increased risk of suicidality in children and young adults (≤24 years) in short-term studies of major depressive disorder (MDD) and other psychiatric disorders. Avoid abrupt discontinuation; withdrawal symptoms can occur with sudden discontinuation of selective serotonin reuptake inhibitors (SSRIs) and serotonin/norepinephrine reuptake inhibitors (SNRIs), paroxetine and venlafaxine in particular. Paroxetine and sertraline have FDA indications for treating PTSD. Common adverse effects of the SSRIs and SNRIs include nausea, headache, diarrhea, nervousness, sexual dysfunction, dizziness. Hyponatremia or syndrome of inappropriate antidiuretic hormone (SIADH) can occur; risk is elevated in patients >65 years. Venlafaxine can elevate blood pressure; caution is advised with patients with hypertension. Serotonin syndrome can occur, especially with concomitant medications that affect serotonin.

---

### Pharmacological interventions for prophylaxis of vestibular migraine [^76d88925]. The Cochrane Database of Systematic Reviews (2023). Medium credibility.

Quality of the evidence

We assessed all the evidence in this review as either low‐ or very low‐certainty, using the GRADE approach. This shows that our confidence in the estimates of effect is low, and that additional data from future studies are likely to change these estimates.

Imprecision in the effect estimates was a major contributor to the low certainty of the evidence. The studies included in this review were all relatively small (ranging from 27 to 130 participants), and often the confidence intervals for any effect were wide, sometimes ranging from the possibility of a beneficial effect to the possibility of a harmful effect from the intervention.

We had concerns over the risk of bias for the studies included in the review. The studies Lepcha 2014 and Yuan 2016 were open‐label, where participants and study personnel were aware of the treatment allocation, leading to a high risk of performance bias and detection bias. There were also additional concerns in other domains for both of these studies. We considered the largest study at low risk of bias for most domains (Bayer 2019). However, due to considerable dropout during the trial we assessed it at high risk of attrition bias. However, we also had concerns over the possibility of selective reporting bias, as outcomes were not reported at the intended final follow‐up point.

As described above, we also had some concerns over the methods used to assess some outcomes. The certainty of the evidence was reduced for indirectness if the outcome had been assessed using an unvalidated scale, or the outcome reported did not fully align with our pre‐specified outcomes of interest. This was the case for improvement in vertigo and headache as reported by Lepcha 2014, where they compared participants with 'marked improvement' to those with 'little or no improvement', when we were intending to assess those with 'any improvement' compared to none.

---

### Systemic pharmacological interventions for Ménière's disease [^39c4812f]. The Cochrane Database of Systematic Reviews (2023). Medium credibility.

Sensitivity analysis

We planned to carry out a number of sensitivity analyses for the primary outcomes in this review. However, the paucity of data and the lack of meta‐analyses has meant that this was not possible.

If few studies are identified for meta‐analysis, the random‐effects model may provide an inaccurate measure of the between‐studies variance. Therefore, we planned to explore the impact of using a fixed‐effect model using a sensitivity analysis. However, few meta‐analyses were conducted, and these analyses were actually carried out using the Peto OR, a fixed‐effect method, due to zero events in at least one arm of a study. For completeness, we have compared the results to a random‐effects method using the Mantel‐Haenzel OR, but the results are very similar (Table 7).

5 
Sensitivity analysis

If there was uncertainty over the diagnostic criteria used for participants in the studies (for example, if it was not clear whether participants were diagnosed using criteria that are analogous to the AAO‐HNS criteria) then we also planned to explore this by including/excluding those studies from the analysis. However, as noted above we had such sparse data in the review that we were unable to conduct these analyses.

We used the Cochrane Pregnancy and Childbirth Screening Tool to identify any studies with concerns over the data available. We had intended that any studies identified by the tool would be excluded from the main analyses in the review, but that we would explore the impact of including the data from these studies through a sensitivity analysis. However, as noted above, we had some concerns over the use of this tool, and few studies were included in the review, therefore this sensitivity analysis was not conducted.

We did conduct one sensitivity analysis that was not pre‐specified in our protocol (Webster 2021b). When drafting the protocol for this review we stated "improvement in vertigo" as our outcome. However, over the course of the review it became apparent that "any improvement" may not represent a meaningful improvement for people with Ménière's disease. For example, an individual who suffered 100 vertigo attacks per year at baseline and then only 99 attacks per year at follow‐up could be stated to have 'improved' ‐ although it is not clear whether the difference would be of any importance. For our main analysis for this outcome we considered 'any improvement' in vertigo, but we also conducted a sensitivity analysis to see if the effect estimates were altered if we considered 'substantial improvement' in vertigo.

---

### Vestibular migraine treatment: a comprehensive practical review [^c8dbbaba]. Brain (2022). Medium credibility.

Beta-blockers

Beta-blockers are commonly used for migraine treatment, although the mechanism of action in migraine is incompletely understood.There were four studies of propranolol in VM and one of metoprolol. Propranolol was associated with reductions in vertigo frequency and severity using before-and-after comparisons. Doses in the studies varied: 40 mg twice daily for weight <60 kg and 60 mg twice daily for weight >60 kg,up to 80 mg twice daily,10 mg once dailyand 40 mg and 80 mg once daily (two different treatment arms).A retrospective, uncontrolled studyfollowed 38 patients prescribed propranolol 80–120 mg daily for between 6 and 32 months. Due to the variable follow-up, the authors attempted to standardize the duration of symptoms by converting symptom frequency to 1 year. The mean ‘annual duration of symptoms’ was 115 days before treatment and 13 days after treatment (P < 0.001); however, this was an extrapolation and likely to have been inaccurate. Mean vertigo severity (VAS 0–10) reduced from 7.52 to 1.34 (P < 0.001) and the dizziness handicap inventory (DHI), a well-validated measure of the impact of dizziness disability, reduced from 50.21 to 9.31 (P < 0.001). The vertigo symptom scale (VSS) and a quality-of-life measure (vestibular activities of daily living scale, VADL) were also lower after treatment. An unblinded RCT comparing propranolol 40–160 mg daily (n = 26) and venlafaxine 37.5–150 mg daily (n = 26) for 4 months found no significant differences between the two treatments, except that propranolol was inferior for depressive symptoms.A before-and-after analysis was also performed, and patients receiving propranolol showed marked reductions in mean monthly vertigo frequency (from 12.6 to 1.9, P < 0.001), DHI (55.8–31.3, P < 0.001), VAS vertigo severity (7.3–2.1, P < 0.001) and the Beck Anxiety Inventory (BAI). Two small observational studies compared outcomes in patients receiving multiple treatments including propranolol. These studies found improvements in subjective measures of vertigo and headache severity from pre- to post-treatment but were underpowered to detect between-group differences. Propranolol has never been compared to a placebo (or a control group without placebo) in VM and thus some of the benefits seen in the studies could be due to this confound.

---

### Venlafaxine hydrochloride [^8f884189]. FDA (2025). Medium credibility.

5.7 Discontinuation Syndrome

Discontinuation symptoms have been systematically evaluated in patients taking venlafaxine, including prospective analyses of clinical studies in GAD and retrospective surveys of studies in MDD and SAD. Abrupt discontinuation or dose reduction of venlafaxine at various doses has been found to be associated with the appearance of new symptoms, the frequency of which increased with increased dose level and with longer duration of treatment. Reported symptoms include agitation, anorexia, anxiety, confusion, impaired coordination and balance, diarrhea, dizziness, dry mouth, dysphoric mood, fasciculation, fatigue, flu-like symptoms, headaches, hypomania, insomnia, nausea, nervousness, nightmares, sensory disturbances (including shock-like electrical sensations), somnolence, sweating, tremor, vertigo, and vomiting.

There have been postmarketing reports of serious discontinuation symptoms which can be protracted and severe. Completed suicide, suicidal thoughts, aggression and violent behavior have been observed in patients during reduction in venlafaxine hydrochloride extended-release capsules dosage, including during discontinuation. Other postmarketing reports describe visual changes (such as blurred vision or trouble focusing) and increased blood pressure after stopping or reducing the dose of venlafaxine hydrochloride extended-release capsules.

During marketing of venlafaxine hydrochloride extended-release capsules, other SNRIs, and SSRIs, there have been reports of adverse events occurring upon discontinuation of these drugs, particularly when abrupt, including the following: irritability, lethargy, emotional lability, tinnitus, and seizures.

Patients should be monitored for these symptoms when discontinuing treatment with venlafaxine hydrochloride extended-release capsules. A gradual reduction in the dose, rather than abrupt cessation, is recommended. If intolerable symptoms occur following a decrease in the dose or upon discontinuation of treatment, then resuming the previously prescribed dose may be considered. Subsequently, the healthcare provider may continue decreasing the dose, but at a more gradual rate. In some patients, discontinuation may need to occur over a period of several months [see Dosage and Administration (2.10)].

5.8 Seizures

Cases of seizure have been reported with venlafaxine therapy. venlafaxine hydrochloride extended-release capsules has not been systematically evaluated in patients with seizure disorder. venlafaxine hydrochloride extended-release capsules should be prescribed with caution in patients with a seizure disorder.

---

### Guidelines for reasonable and appropriate care in the emergency department 3 (GRACE-3): acute dizziness and vertigo in the emergency department [^bf822e41]. Academic Emergency Medicine (2023). High credibility.

Selection of outcomes of interest—each subcommittee chose outcomes judged most important by the writing group including the three patient representatives; for the three diagnostic questions the outcomes related to accurate diagnosis, and for the fourth and fifth therapy questions the outcomes focused on symptom relief and other markers of improvement.

---

### The 2023 nonhormone therapy position statement of the North American Menopause Society [^0bdc33a0]. Menopause (2023). High credibility.

Clonidine—comparative benefit, adverse effects, and recommendation: Clonidine has been shown to be modestly more beneficial than placebo but less beneficial than SSRIs, SNRIs, and gabapentin in reducing VMS; it is used infrequently because of adverse effects such as hypotension, lightheadedness, headache, dry mouth, dizziness, sedation, and constipation, and sudden cessation can lead to significant elevations in blood pressure. Because other therapies are more effective with fewer adverse effects, clonidine is not recommended (Levels I-III; not recommended).

---

### Systemic pharmacological interventions for Ménière's disease [^82dd23fe]. The Cochrane Database of Systematic Reviews (2023). Medium credibility.

Background

Description of the condition

Ménière's disease was first described by Prosper Ménière in 1861 as a condition characterised by episodes of vertigo, associated with hearing loss and tinnitus (Baloh 2001). Sufferers may also report a feeling of fullness in the affected ear. Typically, it initially affects one ear, although some individuals may progress to develop bilateral disease. A hallmark of the condition is that symptoms are intermittent ‐ occurring as discrete attacks that last from minutes to several hours, then resolve. However, over time there is usually a gradual deterioration in hearing, and there may be progressive loss of balance function, leading to chronic dizziness.

The diagnosis of Ménière's disease is challenging, due to the episodic nature of the condition, clinical heterogeneity and the lack of a 'gold standard' diagnostic test. Even the agreed, international classification system has scope for two categories of diagnosis – 'definite' and 'probable' (Lopez‐Escamez 2015). In brief, a diagnosis of definite Ménière's disease requires at least two episodes of vertigo, each lasting 20 minutes to 12 hours, together with audiometrically confirmed hearing loss and fluctuating aural symptoms (reduction in hearing, tinnitus or fullness) in the affected ear. 'Probable' Ménière's disease includes similar features, but without the requirement for audiometry to diagnose hearing loss, and with scope for the vertigo episodes to last longer (up to 24 hours). Both categories ('definite' and 'probable') require that the symptoms are not more likely to be due to an alternative diagnosis, due to the recognised challenges in distinguishing between balance disorders.

---

### Update on the pharmacotherapy of cerebellar and central vestibular disorders [^0b0e949a]. Journal of Neurology (2016). Low credibility.

Vestibular migraine

Vestibular migraine is a form of migraine in which the patient experiences recurrent attacks of vertigo or dizziness. More recently, the diagnostic criteria were defined more precisely by the Classification Committee of Vestibular Disorders of the Barany Society together with the International Classification of Headache Disorders (ICHD). The criteria are as follows: 1. at least five episodes with vestibular symptoms of moderate or severe intensity, lasting 5 min to 72 h; 2. current or previous history of migraine with or without aura according to the ICHD; 3. one or more migraine features with at least 50 % of the vestibular episodes: 3a. headache with at least two of the following characteristics: one-sided location, pulsating quality, moderate or severe pain intensity, aggravation by routine physical activity; 3b. photophobia and phonophobia; 3c. visual aura; 4. not better accounted for by another vestibular or ICHD diagnosis.

Several drugs are widely used for vestibular migraine either for the attacks or as a prophylactic treatment to reduce the frequency; however, none of them has proven their efficacy in clinical trials and the need for state-of-the-art randomized controlled trials was identified in a recent Cochrane Review. There is an ongoing multicenter, double-blind, placebo-controlled trial on the prophylactic treatment of vestibular migraine with metoprolol 95 mg per day [University of Munich (PROVEMIG-trial, funded by the Federal Ministry of Education and Research)].

---

### Clinical practice guideline: benign paroxysmal positional vertigo (update) [^e12d079c]. Otolaryngology--Head and Neck Surgery (2017). Medium credibility.

Financial disclosure and conflicts of interest—support and management procedures included full coverage of development costs by the AAO-HNSF, systematic conflict tracking over the past 5 years, and explicit conditions for panelists with potential conflicts. Individuals could remain if they (1) reminded the panel of any potential conflicts before related discussion, (2) recused themselves from related discussion if asked, and (3) agreed not to discuss the guideline with industry before publication; panelists were also reminded that conflicts extend beyond financial relationships.

---

### Venlafaxine hydrochloride [^6c08d5fa]. FDA (2024). Medium credibility.

During marketing of venlafaxine hydrochloride extended-release capsules, other SNRIs, and SSRIs, there have been spontaneous reports of adverse events occurring upon discontinuation of these drugs, particularly when abrupt, including the following: dysphoric mood, irritability, agitation, dizziness, sensory disturbances (e.g., paresthesia, such as electric shock sensations), anxiety, confusion, headache, lethargy, emotional lability, insomnia, hypomania, tinnitus, and seizures. While these events are generally self-limiting, there have been reports of serious discontinuation symptoms.

Patients should be monitored for these symptoms when discontinuing treatment with venlafaxine hydrochloride extended-release capsules. A gradual reduction in the dose, rather than abrupt cessation, is recommended whenever possible. If intolerable symptoms occur following a decrease in the dose or upon discontinuation of treatment, then resuming the previously prescribed dose may be considered. Subsequently, the physician may continue decreasing the dose, but at a more gradual rate [see Dosage and Administration (2.8)].

5.8 Seizures

Seizures have occurred with venlafaxine therapy. Venlafaxine hydrochloride extended-release capsules like many antidepressants, should be used cautiously in patients with a history of seizures and should be discontinued in any patient who develops seizures. [Must mitigate the risk: Risk factors, concomitant meds that lower the seizure threshold.]

---

### Pharmacological interventions for persistent postural-perceptual dizziness (PPPD) [^e4fd736c]. The Cochrane Database of Systematic Reviews (2023). Medium credibility.

Types of outcome measures

We planned to assess outcomes at the following time points:

3 to < 6 months;
6 to ≤ 12 months;
> 12 months.

The exception was for adverse event data, when we planned to use the longest time period of follow‐up.

We searched the COMET database for existing core outcome sets of relevance to PPPD and vertigo, but were unable to find any published core outcome sets. We therefore conducted a survey of individuals with experience of (or an interest in) balance disorders to help identify outcomes that should be prioritised. This online survey was conducted with the support of the Ménière's Society and the Migraine Trust, and included 324 participants, who provided information regarding priority outcomes. The review author team used the results of this survey to inform the choice of outcome measures in this review.

We planned to analyse the following outcomes in the review, but we did not use them as a basis for including or excluding studies.

Primary outcomes

Improvement in vestibular symptoms Measured as a dichotomous outcome (improved/not improved), according to self‐report, or according to a change of a specified score (as described by the study authors) on a rating scale.
Change in vestibular symptoms Measured as a continuous outcome, to identify the extent of change in vestibular symptoms.
Serious adverse events Including any event that caused death, was life‐threatening, required hospitalisation, resulted in disability or permanent damage, or in congenital abnormality. Measured as the number of participants who experienced at least one serious adverse event during the follow‐up period.

Secondary outcomes

Disease‐specific health‐related quality of life Measured with the Dizziness Handicap Inventory (DHI, Jacobsen 1990); the DHI short form (Tesio 1999); or the DHI screening tool (Jacobsen 1998).
Generic health‐related quality of life Measured with a validated measurement tool that assesses global health‐related quality of life, such as the EQ‐5D‐3L (EuroQol 1990), EQ‐5D‐5L (Herdman 2011) or SF‐36 (Ware 1992).
Other adverse effects Measured as the number of participants who experienced at least one episode of the specified adverse events during the follow‐up period, including the following specified adverse effects: headache; gastrointestinal disturbance; sleep disturbance (e.g. somnolence or insomnia); psychological disturbance (e.g. anxiety, depression, agitation); cardiovascular disturbance (e.g. postural lightheadedness, palpitations); sexual dysfunction.

---

### Current validated medical treatments: pharmacologic interventions [^5cdd3c12]. Otolaryngologic Clinics of North America (2020). Medium credibility.

The search for an effective medication that will eliminate tinnitus has a long history. Currently, no drugs exist that universally cure tinnitus. Pharmacologic interventions that have been investigated can be divided into those that attempt to eliminate the perception of tinnitus, and those that are designed to treat the negative comorbidities associated with tinnitus, thereby mitigating tinnitus' negative impact on quality of life. A third category of drugs can also be considered that addresses an identified pathologic condition that has tinnitus as an associated symptom (for example, Meniere's disease, otosclerosis, migraine-associated vertigo). This third category is not addressed.

---

### Non-pharmacological interventions for prophylaxis of vestibular migraine [^92cbb3df]. The Cochrane Database of Systematic Reviews (2023). Medium credibility.

1. Improvement in vertigo

For this outcome we included dichotomous data, assessed as the proportion of participants whose vertigo had 'improved' or 'not improved'.

1.1. Global score

None of the included studies assessed the improvement in vertigo using a global score.

1.2. Frequency

This outcome was not reported by any of the studies. We note that the methods section of Qi 2020 indicated that vertigo would be assessed as a categorical outcome: "The reduction in the attack number was categorized as complete resolution, substantial control (>50% decrease), moderate control (25‐50% decrease), and minimal control (<25% decrease) with unaltered or increased frequency". However, these data are not presented in the article.

2. Change in vertigo

This outcome included data on the change in vertigo using a continuous numerical scale.

2.1. Global score

Qi 2020 reported assessing the change in vertigo using a vertigo severity score "which reflects the seriousness of vertiginous attack that negatively affects the life quality of the patients". However, it was unclear whether the scoring system used reflects vertigo symptoms or quality of life. The scoring range appeared to be from 1 to 10 (with higher scores representing worse symptoms).

McPhee 2017 assessed change in vertigo using the Vertigo Symptom Scale Short Form (VSS‐SF). This is a 15‐item instrument that assesses symptoms over the course of one month, with a total score of 0 to 60 (higher scores represent worse symptoms). The data from this instrument actually considers both vertigo symptoms (vestibular‐balance subscale, range 0 to 32), and also some additional associated symptoms (autonomic‐anxiety subscale, range 0 to 28). As the results of the vestibular‐balance subscale were not reported, we were only able to include the total score in the analysis.

Aydin 2020 did not assess the change in vertigo using a global score.

2.2. Frequency

Qi 2020 reported on the change in the frequency of vertigo attacks, by recording the number of vertigo attacks per week. Aydin 2020 assessed the frequency of vertigo attacks per month.

This outcome was not assessed by McPhee 2017

3. Serious adverse events

It was not clear whether any of the studies systematically assessed the occurrence of serious adverse events.

4. Disease‐specific health‐related quality of life

All three studies assessed this outcome using the Dizziness Handicap Inventory (DHI).

---

### Antimigraine and antidepressant drug coprescription and serotonin syndrome (...) [^50ec4329]. JAMA Network (2018). Excellent credibility.

The proportion of patients with triptan prescriptions who were coprescribed an SSRI or SNRI antidepressant was relatively stable during the study, ranging from 21% to 29%. Conclusions and Relevance The risk of serotonin syndrome associated with concomitant use of triptans and SSRIs or SNRIs was low. Coprescription of these drugs is common and did not decrease after the 2006 FDA advisory. Our results cast doubt on the validity of the FDA advisory and suggest that it should be reconsidered. It causes a constellation of features, including tachycardia, unstable blood pressure, hyperthermia, nausea, vomiting, and diarrhea. Severity varies, but it can be fatal. 3 The FDA advisory was based on a small number of case reports. Doubts exist about whether these cases actually met criteria for the disorder. 4, 5 A position paper by the American Headache Society questioned the basis for the advisory and noted conflicting and insufficient information to discern the risk.
6.

Agitation Tremor Myoclonus Hyperreflexia Diaphoresis Shivering Diarrhea Incoordination Fever One or more of the following in the presence of a serotonergic drug: Spontaneous clonus Inducible clonus and agitation or diaphoresis. Review of individual medical records revealed that serotonin syndrome had been clinically suspected in 17 of these 229 patients. Suspected diagnoses in the other 212 patients included restless legs syndrome, periodic limb movement disorder of sleep diagnosed by polysomnography, akathisia attributed to dopaminergic drugs, dystonia, tremor, nocturnal myoclonus, poststroke spasticity, and other abnormal movements. Our results provide additional reasons to be skeptical that triptans increase the risk of serotonin syndrome beyond the risk already associated with SSRI and SNRIs alone. SSRI and SNRI antidepressants are more firmly established as a cause of serotonin syndrome.

In one study, 13 serotonin syndrome was diagnosed in 14% of patients with SSRI overdose. In patients taking the SSRI antidepressant nefazodone, the incidence of serotonin syndrome was estimated to be 0. 5 to
0. 9 cases per 1000 patient-months of treatment. 14.

---

### Fluoxetine hydrochloride (fluoxetine) [^f6df268a]. FDA (2025). Medium credibility.

5.15 Discontinuation Adverse Reactions

During marketing of fluoxetine, SNRIs, and SSRIs, there have been spontaneous reports of adverse reactions occurring upon discontinuation of these drugs, particularly when abrupt, including the following: dysphoric mood, irritability, agitation, dizziness, sensory disturbances (e.g., paresthesias such as electric shock sensations), anxiety, confusion, headache, lethargy, emotional lability, insomnia, and hypomania. While these reactions are generally self-limiting, there have been reports of serious discontinuation symptoms. Patients should be monitored for these symptoms when discontinuing treatment with fluoxetine. A gradual reduction in the dose rather than abrupt cessation is recommended whenever possible. If intolerable symptoms occur following a decrease in the dose or upon discontinuation of treatment, then resuming the previously prescribed dose may be considered. Subsequently, the healthcare provider may continue decreasing the dose but at a more gradual rate. Plasma fluoxetine and norfluoxetine concentration decrease gradually at the conclusion of therapy which may minimize the risk of discontinuation symptoms with this drug.

5.16 Fluoxetine and Olanzapine in Combination

When using fluoxetine and olanzapine in combination, also refer to the Warnings and Precautions section of the package insert for Symbyax.

5.17 Sexual Dysfunction

Use of SSRIs, including fluoxetine, may cause symptoms of sexual dysfunction [see Adverse Reactions (6.1)]. In male patients, SSRI use may result in ejaculatory delay or failure, decreased libido, and erectile dysfunction. In female patients, SSRI use may result in decreased libido and delayed or absent orgasm.

It is important for prescribers to inquire about sexual function prior to initiation of fluoxetine and to inquire specifically about changes in sexual function during treatment, because sexual function may not be spontaneously reported. When evaluating changes in sexual function, obtaining a detailed history (including timing of symptom onset) is important because sexual symptoms may have other causes, including the underlying psychiatric disorder. Discuss potential management strategies to support patients in making informed decisions about treatment.

---

### Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) for the prevention of migraine in adults [^f4f5fec5]. The Cochrane Database of Systematic Reviews (2015). Low credibility.

Background

This is an updated version of the original Cochrane review published in 2005 on selective serotonin reuptake inhibitors (SSRIs) for preventing migraine and tension-type headache. The original review has been split in two parts and this review now only regards migraine prevention. Another updated review is under development to cover tension-type headache.Migraine is a common disorder. The chronic forms are associated with disability and have a high economic impact. In view of discoveries about the role of serotonin and other neurotransmitters in pain mechanisms, selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) have been evaluated for the prevention of migraine.

Objectives

To determine the efficacy and tolerability of SSRIs and SNRIs compared to placebo and other active interventions in the prevention of episodic and chronic migraine in adults.

Search Methods

For the original review, we searched MEDLINE (1966 to January 2004), EMBASE (1994 to May 2003), the Cochrane Central Register of Controlled Trials (CENTRAL 2003, Issue 4), and Headache Quarterly (1990 to 2003). For this update, we applied a revised search strategy to reflect the broader type of intervention (SSRIs and SNRIs). We searched CENTRAL (2014, Issue 10), MEDLINE (1946 to November 2014), EMBASE (1980 to November 2014), and PsycINFO (1987 to November 2014). We also checked the reference lists of retrieved articles and searched trial registries for ongoing trials.

Selection Criteria

We included randomised controlled trials comparing SSRIs or SNRIs with any type of control intervention in participants 18 years and older of either sex with migraine.

Data Collection and Analysis

Two authors independently extracted data (migraine frequency, index, intensity, and duration; use of symptomatic/analgesic medication; days off work; quality of life; mood improvement; cost-effectiveness; and adverse events) and assessed the risk of bias of trials. The primary outcome of this updated review is migraine frequency.

Main Results

The original review included eight studies on migraine. Overall, we now include 11 studies on five SSRIs and one SNRI with a total of 585 participants. Six studies were placebo-controlled, four compared a SSRI or SNRI to amitriptyline, and one was a head-to-head comparison (escitalopram versus venlafaxine). Most studies had methodological or reporting shortcomings (or both): all studies were at unclear risk of selection and reporting bias. Follow-up rarely extended beyond three months. The lack of adequate power of most of the studies is also a major concern.Few studies explored the effect of SSRIs or SNRIs on migraine frequency, the primary endpoint. Two studies with unclear reporting compared SSRIs and SNRIs to placebo, suggesting a lack of evidence for a difference. Two studies compared SSRIs or SNRIs versus amitriptyline and found no evidence for a difference in terms of migraine frequency (standardised mean difference (SMD) 0.04, 95% confidence interval (CI) -0.72 to 0.80; I(2) = 72%), or other secondary outcomes such as migraine intensity and duration.SSRIs or SNRIs were generally more tolerable than tricyclics. However, the two groups did not differ in terms of the number of participants who withdrew due to adverse advents or for other reasons (one study, odds ratio (OR) 0.39, 95% CI 0.10 to 1.50 and OR 0.42, 95% CI 0.13 to 1.34).We did not find studies comparing SSRIs or SNRIs with pharmacological treatments other than antidepressants (e.g. antiepileptics and anti-hypertensives).

Authors' Conclusions

Since the last version of this review, the new included studies have not added high quality evidence to support the use of SSRIs or venlafaxine as preventive drugs for migraine. There is no evidence to consider SSRIs or venlafaxine as more effective than placebo or amitriptyline in reducing migraine frequency, intensity, and duration over two to three months of treatment. No reliable information is available at longer-term follow-up. Our conclusion is that the use of SSRIs and SNRIs for migraine prophylaxis is not supported by evidence.

---

### Clinical practice guideline: benign paroxysmal positional vertigo (update) [^5b5f5787]. Otolaryngology--Head and Neck Surgery (2017). Medium credibility.

Regarding follow-up and surveillance for dizziness and vertigo, more specifically with respect to vestibular rehabilitation (AAO-HNSF), AAO-HNS 2017 guidelines recommend to consider offering vestibular rehabilitation, either self-administered or administered by a clinician, in the treatment of patients with benign paroxysmal positional vertigo.

---

### Systemic pharmacological interventions for Ménière's disease [^5431048b]. The Cochrane Database of Systematic Reviews (2023). Medium credibility.

Background

Ménière's disease is a condition that causes recurrent episodes of vertigo, associated with hearing loss and tinnitus. A number of pharmacological interventions have been used in the management of this condition, including betahistine, diuretics, antiviral medications and corticosteroids. The underlying cause of Ménière's disease is unknown, as is the way in which these treatments may work. The efficacy of these different interventions at preventing vertigo attacks, and their associated symptoms, is currently unclear.

Objectives

To evaluate the benefits and harms of systemic pharmacological interventions versus placebo or no treatment in people with Ménière's disease.

Search Methods

The Cochrane ENT Information Specialist searched the Cochrane ENT Register; Central Register of Controlled Trials (CENTRAL); Ovid MEDLINE; Ovid Embase; Web of Science; ClinicalTrials.gov; ICTRP and additional sources for published and unpublished trials. The date of the search was 14 September 2022.

Selection Criteria

We included randomised controlled trials (RCTs) and quasi-RCTs in adults with definite or probable Ménière's disease comparing betahistine, diuretics, antihistamines, antivirals or systemic corticosteroids with either placebo or no treatment. We excluded studies with follow-up of less than three months, or with a cross-over design (unless data from the first phase of the study could be identified).  DATA COLLECTION AND ANALYSIS: We used standard Cochrane methods. Our primary outcomes were: 1) improvement in vertigo (assessed as a dichotomous outcome - improved or not improved), 2) change in vertigo (assessed as a continuous outcome, with a score on a numerical scale) and 3) serious adverse events. Our secondary outcomes were: 4) disease-specific health-related quality of life, 5) change in hearing, 6) change in tinnitus and 7) other adverse effects. We considered outcomes reported at three time points: 3 to < 6 months, 6 to ≤ 12 months and > 12 months. We used GRADE to assess the certainty of evidence for each outcome.  MAIN RESULTS: We included 10 studies with a total of 848 participants. The studies evaluated the following interventions: betahistine, diuretics, antivirals and corticosteroids. We did not identify any evidence on antihistamines.  Betahistine Seven RCTs (548 participants) addressed this comparison. However, we were unable to conduct any meta-analyses for our primary outcomes as not all outcomes were considered by every study, and studies that did report the same outcome used different time points for follow-up, or assessed the outcome using different methods. Therefore, we were unable to draw meaningful conclusions from the numerical results. Some data were available for each of our primary outcomes, but the evidence was low- or very low-certainty throughout. One study reported on the outcome 'improvement in vertigo' at 6 to ≤ 12 months, and another study reported this outcome at > 12 months. Four studies reported on the change in vertigo, but again all used different methods of assessment (vertigo frequency, or a global score of vertigo severity) or different time points. A single study reported on serious adverse events.  Diuretics Two RCTs addressed this comparison. One considered the use of isosorbide (220 participants), and the other used a combination of amiloride hydrochloride and hydrochlorothiazide (80 participants). Again, we were unable to conduct any meta-analyses for our primary outcomes, as only one study reported on the outcome 'improvement in vertigo' (at 6 to ≤ 12 months), one study reported on change in vertigo (at 3 to < 6 months) and neither study assessed serious adverse events. Therefore, we were unable to draw meaningful conclusions from the numerical results. The evidence was all very low-certainty.  Other pharmacological interventions We also identified one study that assessed antivirals (24 participants), and one study that assessed corticosteroids (16 participants). The evidence for these interventions was all very low-certainty. Again, serious adverse events were not considered by either study.

Authors' Conclusions

The evidence for systemic pharmacological interventions for Ménière's disease is very uncertain. There are few RCTs that compare these interventions to placebo or no treatment, and the evidence that is currently available from these studies is of low or very low certainty. This means that we have very low confidence that the effects reported are accurate estimates of the true effect of these interventions. Consensus on the appropriate outcomes to measure in studies of Ménière's disease is needed (i.e. a core outcome set) in order to guide future studies in this area and enable meta-analyses of the results. This must include appropriate consideration of the potential harms of treatment, as well as the benefits.

---

### ACR appropriateness criteriaHearing loss and / or Vertigo [^afc8d454]. Journal of the American College of Radiology (2018). Medium credibility.

Regarding diagnostic investigations for dizziness and vertigo, more specifically with respect to diagnostic imaging (persistent vertigo), ACR 2018 guidelines recommend to obtain head and internal auditory canal MRI in patients with persistent vertigo with or without neurological symptoms (central vertigo).

---

### Pharmacotherapy of vestibular and ocular motor disorders, including nystagmus [^2ef63728]. Journal of Neurology (2011). Low credibility.

Central vestibular disorders

Vestibular migraine

Vestibular migraine is increasingly regarded as the most common central cause of recurrent attacks of vertigo. Characteristic features include recurrent attacks of various combinations of vertigo, ataxia of stance and gait, photophobia and phonophobia, and other brainstem symptoms, accompanied or followed by head pressure, pain, nausea, or vomiting. Treatment is the same as for migraine with aura: beta-blockers (metoprolol or propranolol), valproic acid, or topiramate for at least 3–6 months. Several treatment trials have been performed in patients with vestibular migraine. Tricyclic antidepressants in combination with diet gave a good response (>95%) in a noncontrolled trial on 81 patients. For zolmitriptan, the response rate in acute attacks was 38 versus 22% for placebo in a study on 19 patients. Another open trial on 10 patients demonstrated that lamotrigine (100 mg/day as a single dose) had a significant effect on the occurrence of headache and a more marked effect on vertigo. The treatment options have been summarized in a retrospective study. At present, only standard treatments for migraine with aura can be recommended for vestibular migraine. A placebo-controlled, multicenter trial to evaluate the efficacy of metoprolol on the frequency of attacks in vestibular migraine has been initiated (PROVEMIG EudraCT No. 2009-013701-34).

In summary, the pharmacotherapy of vestibular migraine has not yet been evaluated with state-of-the-art clinical trials. Consequently, only drugs that are effective for treating migraine with and without aura can currently be recommended. For the therapy of acute attacks, aspirin and an antiemetic could be offered, whereas metoprolol (100 mg/day), topiramate (50–100 mg/day), or valproic acid (300–900 mg/day) could be offered for prophylaxis.

---

### Systemic pharmacological interventions for Ménière's disease [^30c834e9]. The Cochrane Database of Systematic Reviews (2023). Medium credibility.

Subgroup analysis and investigation of heterogeneity

If statistical heterogeneity was identified for any comparison, we planned to assess this considering the following subgroups:

different types of medication, within a specific class;
different doses/frequency of administration;
use of concomitant treatment;
diagnosis of Ménière's disease

However, due to the paucity of data available, and the few meta‐analyses included in this review, we did not carry out any subgroup analysis.

---

### Migrainous vertigo, tinnitus, and ear symptoms and alternatives [^170948e3]. Otolaryngologic Clinics of North America (2022). Medium credibility.

Migraine headaches frequently coexist with vestibular symptoms such as vertigo, motion sickness, and gait instability. Migraine-related vasospasm can also damage the inner ear, which results in symptoms such as sudden sensorineural hearing loss and resultant tinnitus. The pathophysiology of these symptoms is not yet fully understood, and despite their prevalence, there is no universally approved management. This review summarizes the data on complementary and integrative medicine in treating patients with migrainous ear disorders.

---

### Rizatriptan vs placebo for attacks of vestibular migraine: a randomized clinical trial [^a0df7c58]. JAMA Neurology (2025). High credibility.

Importance

Vestibular migraine has no established treatments.

Objective

To test the efficacy of rizatriptan for treating vestibular migraine attacks.

Design, Setting, and Participants

This double-blind, randomized clinical trial of rizatriptan vs placebo was conducted from December 2014 through July 2020 (data analyses in 2021 and sensitivity analyses in 2022 and 2024) at 2 tertiary neurotologic centers. Adults with vestibular migraine were included.

Intervention

All participants underwent prospective observation to confirm diagnosis and illness activity and were then randomized in a 2:1 ratio to receive rizatriptan 10 mg or placebo to treat up to 3 vestibular migraine attacks per participant.

Main Outcomes and Measures

Participants rated symptoms as absent, mild, moderate, or severe at scheduled intervals. Primary outcomes were the percentage of attacks with reductions in vertigo and unsteadiness/dizziness from moderate or severe to absent or mild at 1 hour. Secondary outcomes were the percentage of attacks with complete resolution of vestibular symptoms at 1 hour; reductions in headache and associated symptoms at 1 hour; use of rescue medications after 1 hour; reductions in vestibular, headache, and associated symptoms at 24 hours without rescue medications; treatment satisfaction and quality of life at 48 hours; and rates of serious adverse effects and discontinuation due to adverse effects.

Results

Of 222 total participants (mean [SD] age, 42.3 [11.7] years; 70.7% were women), 134 (60.4%) with active illness treated 307 attacks. Efficacy was tested using 240 attacks with vestibular symptoms rated as moderate or severe when participants took study drug. At 1 hour, rizatriptan did not differ from placebo for reducing vertigo (73/151 [48.3%] vs 50/88 [56.8%] attacks; odds ratio [OR], 0.71 [95% CI, 0.42-1.21]), unsteadiness/dizziness (29/151 [19.2%] vs 11/89 [12.4%] attacks; OR, 1.69 [95% CI, 0.80-3.57]), or any secondary outcomes. Similar percentages of participants in rizatriptan and placebo groups (26.4% for both groups) added rescue remedies after 1 hour. At 24 hours, rizatriptan had medium effects over placebo for unsteadiness/dizziness (OR, 2.65) and motion sensitivity (OR, 3.58). Post hoc analyses of all treated attacks found a medium effect favoring rizatriptan for headache and photophobia or phonophobia at 24 hours. Treatment satisfaction was equivocal. Quality of life was mixed. No participants experienced serious adverse effects or discontinued treatment for adverse effects.

Conclusions and Relevance

In this study, rizatriptan was ineffective at 1 hour for treating vestibular migraine attacks and had limited benefit on symptoms at 24 hours. Findings do not support using rizatriptan for vestibular migraine attacks.

Trial Registration

ClinicalTrials.gov Identifier: NCT02447991.

---

### Clinical practice guideline: benign paroxysmal positional vertigo (update) [^384d7d5d]. Otolaryngology--Head and Neck Surgery (2017). Medium credibility.

Regarding diagnostic investigations for dizziness and vertigo, more specifically with respect to vestibular function testing (AAO-HNSF), AAO-HNS 2017 guidelines recommend to do not obtain routine vestibular testing in patients meeting diagnostic criteria for benign paroxysmal positional vertigo without additional vestibular signs and/or symptoms warranting testing.

---

### Clinical practice guideline: Ménière's disease [^71b45007]. Otolaryngology--Head and Neck Surgery (2020). High credibility.

Action statement attributes—intentional vagueness is None, the role of patient preferences is Large depending on severity of symptoms, exclusions are None, the policy level is Recommendation, and differences of opinion are None.

---

### Understanding genetic risk factors for common side effects of antidepressant medications [^eb9ad913]. Communications Medicine (2021). Medium credibility.

Discussion

In this study, we aimed at gaining insights into the genetic aetiology of self-reported antidepressant adverse side effects. Our study has several insights, including (1) providing prevalence estimates for side effects outside of a controlled clinical trial; (2) assessing drug-class specificity of antidepressant side effects; (3) testing and providing evidence for non-specific factors (i.e. not related to the type of medication), which is of particular interest for some side effects such as suicidality; and 4) testing for genetic factors underlying the aetiology of side effects using PRS. We identified the most common side effect to be reduced sexual drive or function, followed by weight gain. Reduced sexual function was most prevalent among males taking paroxetine, an SSRI, whereas weight gain was the most prevalent among females taking amitriptyline, a tricyclic antidepressant (TCA). These findings are consistent with research findings showing SSRIs exhibit the most adverse sexual effects, whereas TCAs have been established to cause weight increases.

Studies have suggested that SSRI-based sexual dysfunction may result in 40–65% of individuals ceasing treatment. It is hypothesised that testosterone and dopamine neurotransmitters are dysregulated by SSRIs, a plausible hypothesis considering the role that testosterone plays in sexual function and the high amounts circulating in males compared to females,. Moreover, serotonin plays a crucial role in initiating smooth muscle contraction of the genito-urinary system and regulating the response of the sexual cycle; thus, exogenous substances such as SSRIs that alter these mechanisms may cause sexual dysfunction in both males and females. SNRIs have been reported to lead to more dizziness, trouble sleeping and dry mouth than SSRIs,. We found a higher prevalence for dizziness and sweating from venlafaxine, desvenlafaxine and duloxetine (SNRIs) compared to other antidepressants.

---

### Treatment of symptoms of the menopause: an endocrine society clinical practice guideline [^b5bc8bcd]. The Journal of Clinical Endocrinology and Metabolism (2015). Medium credibility.

Figure 4—hot flash frequency and composite score with nonhormonal prescription therapies for relief of vasomotor symptoms (VMS)—details tolerability, contraindications, and cautions: all of these agents are generally well tolerated, but hypersensitivity or prior adverse drug reactions to each agent represent contraindications; for the SSRIs/SNRIs, prior neuroleptic syndrome, serotonin syndrome, and concurrent use of monoamine oxidase inhibitors are also contraindications; SSRIs/SNRIs should be used with caution in patients with bipolar disease, uncontrolled seizures, hepatic or renal insufficiency, uncontrolled hyponatremia, concurrent use of other SSRIs/SNRIs, or poorly controlled hypertension; these agents uncommonly induce suicidal thoughts within the first few months of treatment and preliminary evidence suggests a possible increase in risk of bone fracture; gabapentin and pregabalin may increase suicidal thoughts and behaviors, cause dizziness or drowsiness, and impair balance and coordination, and pregabalin may impair memory and concentration; clonidine is contraindicated in patients with low blood pressure and may cause lightheadedness, hypotension, headache, and constipation, and sudden cessation of treatment can be associated with significant increases in blood pressure.

---

### Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) for the prevention of tension-type headache in adults [^2139fdec]. The Cochrane Database of Systematic Reviews (2015). Low credibility.

Background

This is an updated version of the Cochrane review published in 2005 on selective serotonin re-uptake inhibitors (SSRIs) for preventing migraine and tension-type headache. The original review has been split in two parts and this review now only regards tension-type headache prevention. Another updated review covers migraine. Tension-type headache is the second most common disorder worldwide and has high social and economic relevance. As serotonin and other neurotransmitters may have a role in pain mechanisms, SSRIs and serotonin-norepinephrine reuptake inhibitors (SNRIs) have been evaluated for the prevention of tension-type headache.

Objectives

To determine the efficacy and tolerability of SSRIs and SNRIs compared to placebo and other active interventions in the prevention of episodic and chronic tension-type headache in adults.

Search Methods

For the original review, we searched the Cochrane Central Register of Controlled Trials (CENTRAL 2003, Issue 4), MEDLINE (1966 to January 2004), EMBASE (1994 to May 2003), and Headache Quarterly (1990 to 2003). For this update, we revised the original search strategy to reflect the broader type of intervention (SSRIs and SNRIs). We searched CENTRAL (2014, Issue 10) on the Cochrane Library, MEDLINE (1946 to November 2014), EMBASE (1980 to November 2014), and PsycINFO (1987 to November 2014). We also checked the reference lists of retrieved articles and searched trial registries for ongoing trials.

Selection Criteria

We included randomised controlled trials comparing SSRIs or SNRIs with any type of control intervention in participants 18 years and older, of either sex, with tension-type headache.

Data Collection and Analysis

Two authors independently extracted data (headache frequency, index, intensity, and duration; use of symptomatic/analgesic medication; quality of life; and withdrawals) and assessed the risk of bias of trials. The primary outcome is tension-type headache frequency, measured by the number of headache attacks or the number of days with headache per evaluation period.

Main Results

The original review included six studies on tension-type headache. We now include eight studies with a total of 412 participants with chronic forms of tension-type headache. These studies evaluated five SSRIs (citalopram, sertraline, fluoxetine, paroxetine, fluvoxamine) and one SNRI (venlafaxine). The two new studies included in this update are placebo controlled trials, one evaluated sertraline and one venlafaxine. Six studies, already included in the previous version of this review, compared SSRIs to other antidepressants (amitriptyline, desipramine, sulpiride, mianserin). Most of the included studies had methodological and/or reporting shortcomings and lacked adequate power. Follow-up ranged between two and four months.Six studies explored the effect of SSRIs or SNRIs on tension-type headache frequency, the primary endpoint. At eight weeks of follow-up, we found no difference when compared to placebo (two studies, N = 127; mean difference (MD) -0.96, 95% confidence interval (CI) -3.95 to 2.03; I(2)= 0%) or amitriptyline (two studies, N = 152; MD 0.76, 95% CI -2.05 to 3.57; I(2)= 44%).When considering secondary outcomes, SSRIs reduce the symptomatic/analgesic medication use for acute headache attacks compared to placebo (two studies, N = 118; MD -1.87, 95% CI -2.09 to -1.65; I(2)= 0%). However, amitriptyline appeared to reduce the intake of analgesic more efficiently than SSRIs (MD 4.98, 95% CI 1.12 to 8.84; I(2)= 0%). The studies supporting these findings were considered at unclear risk of bias. We found no differences compared to placebo or other antidepressants in headache duration and intensity.SSRIs or SNRI were generally more tolerable than tricyclics. However, the two groups did not differ in terms of number of participants who withdrew due to adverse events or for other reasons (four studies, N = 257; odds ratio (OR) 1.04; 95% CI 0.41 to 2.60; I(2)= 25% and OR 1.55, 95% CI 0.71 to 3.38; I(2)= 0%).We did not find any study comparing SSRIs or SNRIs with pharmacological treatments other than antidepressants (e.g. botulinum toxin) or non-drug therapies (e.g. psycho-behavioural treatments, manual therapy, acupuncture).

Authors' Conclusions

Since the last version of this review, the new included studies have not added high quality evidence to support the use of SSRIs or venlafaxine (a SNRI) as preventive drugs for tension-type headache. Over two months of treatment, SSRIs or venlafaxine are no more effective than placebo or amitriptyline in reducing headache frequency in patients with chronic tension-type headache. SSRIs seem to be less effective than tricyclic antidepressants in terms of intake of analgesic medications. Tricyclic antidepressants are associated with more adverse events; however, this did not cause a greater number of withdrawals. No reliable information is available at longer follow-up. Our conclusion is that the use of SSRIs and venlafaxine for the prevention of chronic tension-type headache is not supported by evidence.

---

### Dizziness [^56a519ab]. The American Journal of Medicine (2018). Low credibility.

Dizziness is a common symptom encountered by all physicians. Dizziness and related symptoms are frequently linked to 1 or more of a list of contributors that includes benign paroxysmal positional vertigo, Ménière disease, migraine, acute peripheral vestibulopathy, cerebral ischemia, and anxiety disorders. Awareness of these common clinical patterns increases the likelihood of making a rapid, accurate diagnosis.

---

### 2023 U.S. department of veterans affairs and U.S. department of defense clinical practice guideline for the management of headache [^5722ebc3]. Annals of Internal Medicine (2024). High credibility.

Gabapentin for episodic migraine—trial parameters, efficacy, and adverse events are summarized as follows: In studies using gabapentin at doses ranging between 900–2,400 mg, there was a median 12-week treatment phase (range 12–20 weeks). Regardless of the dose, gabapentin was found to be inefficacious for the treatment of episodic migraine when compared with placebo, and adverse events were higher with gabapentin (68%) versus placebo (57%), including abnormal thinking, somnolence, flu-like syndrome, and dizziness, vertigo or both.

---

### Systemic pharmacological interventions for Ménière's disease [^f8e4a1f2]. The Cochrane Database of Systematic Reviews (2023). Medium credibility.

Why it is important to do this review

Balance disorders can be difficult to diagnose and treat. There are few specific diagnostic tests, a variety of related disorders with similar symptoms and a limited number of interventions that are known to be effective. To determine which topics within this area should be addressed with new or updated systematic reviews we conducted a scoping and prioritisation process, involving stakeholders. Ménière's disease was ranked as one of the highest priority topics during this process (along with vestibular migraine and persistent postural perceptual dizziness).

Although Ménière's disease is a relatively uncommon condition, the significant impact it has on quality of life demonstrates the clear importance of identifying effective interventions to alleviate the symptoms. There is considerable variation in the management of Ménière's disease on both a national and international scale, with a lack of consensus about appropriate first‐line and subsequent therapies.

This review is part of a suite of six that consider different interventions for Ménière's disease. Through these reviews, we hope to provide a thorough summary of the efficacy (benefits and harms) of the different treatment options, to support people with Ménière's disease (and healthcare professionals) when making decisions about their care.

---

### Clinical practice guideline: benign paroxysmal positional vertigo (update) [^01aa76fc]. Otolaryngology--Head and Neck Surgery (2017). Medium credibility.

Table 9—common causes of acute dizziness by timing and triggers categorizes conditions into acute vestibular syndrome, triggered episodic vestibular syndrome, spontaneous episodic vestibular syndrome, and chronic vestibular syndrome. Definitions specify: acute vestibular syndrome is acute persistent continuous dizziness lasting days to weeks and usually associated with nausea, vomiting, and intolerance to head motion; triggered episodic vestibular syndrome is episodic dizziness triggered by specific and obligate actions, usually a change in head or body position, with episodes that generally last <1 minute; spontaneous episodic vestibular syndrome is episodic dizziness that is not triggered and that can last minutes to hours; chronic vestibular syndrome is dizziness lasting weeks to months or longer. Representative causes include: acute vestibular syndrome—vestibular neuritis, labyrinthitis, posterior circulation stroke, demyelinating diseases, posttraumatic vertigo; triggered episodic vestibular syndrome—benign paroxysmal positional vertigo, postural hypotension, perilymph fistula, superior canal dehiscence syndrome, vertebrobasilar insufficiency, central paroxysmal positional vertigo; spontaneous episodic vestibular syndrome—vestibular migraine, Ménière’s disease, posterior circulation transient ischemic attack, medication side effects, anxiety or panic disorder; and chronic vestibular syndrome—anxiety or panic disorder, medication side effects, posttraumatic vertigo, posterior fossa mass lesions, cervicogenic vertigo (variable).

---